493 results on '"Tokyo National Hospital"'
Search Results
2. COVID-19 pandemic
- Author
-
W. J. Fokkens, Jürgen Schwarze, Cezmi A. Akdis, J Mullol, W. Czarlewski, Claudia Traidl-Hoffmann, Claus Bachert, D. Larenas-Linnemann, Tomas Chivato, M. Gotua, Mateo Bonini, Ludger Klimek, Vincenzo Patella, A. A. Cruz, Stephanie Dramburg, Kari C. Nadeau, H W Fritsch, K. Ohta, Thomas Eiwegger, Robert M. Naclerio, Antti Lauerma, A. Yorgancioglu, Aslı Gelincik, Piotr Kuna, Oliver Pfaar, Carmen Riggioni, Violeta Kvedariene, Markus Ollert, Sinthia Bosnic-Anticevich, V. Cardona, S. Del Giacco, Sanna Toppila-Salmi, Helen A. Brough, Heimo Breiteneder, Valérie Hox, B. Samolinski, Zuzana Diamant, G.W. Canonica, Lihong Zhang, María José Torres, Y. Okamoto, Liam O'Mahony, Radosław Gawlik, Jolanta Walusiak-Skorupa, Sharon Chinthrajah, Winfried Rief, T. Haatela, M. Morais-Almeida, Ioana Agache, Manfred Schedlowski, I Skypala, R. Brehler, D. Y. Wang, João Fonseca, I. J. Ansotegui, Robyn E O'Hehir, Oscar Palomares, Charlotte G. Mortz, J. C. Ivancevich, C. Suppli Ulrik, M. T. Ventura, P M Matricardi, S Untersmayr, Gabrielle L. Onorato, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Vanitha Sampath, Arũnas Valiulis, Marek Jutel, Luisa Brussino, Pedro Carreiro-Martins, Jean Bousquet, Nikolaos G. Papadopoulos, A. Bedbrook, Torsten Zuberbier, Karin Hoffmann-Sommergruber, Edward F. Knol, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service d'oto-rhino-laryngologie, Philipps Universität Marburg = Philipps University of Marburg, Allergologie, Stimm und Sprachstörungen [Wiesbaden, Germany], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], University of Wrocław [Poland] (UWr), ALL-MED, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Medizinische Universität Wien = Medical University of Vienna, Stanford University, Skane University Hospital [Malmo], Lund University [Lund], Charles University [Prague] (CU), University Medical Center Groningen [Groningen] (UMCG), Univ Toronto, Hosp Sick Children, Peter Gilgan Ctr Res & Learning, Mol Med, Toronto, ON M5G 0A4, Canada, The Hospital for sick children [Toronto] (SickKids), University of Toronto, Amsterdam UMC - Amsterdam University Medical Center, Alfred Health, Victoria University [Melbourne], University College Cork (UCC), Sean N. Parker Center for Allergy and Asthma Research [Stanford], Stanford Medicine, Stanford University-Stanford University, University Clinics of Essen, University of Essen, Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], Helmholtz Zentrum München = German Research Center for Environmental Health, University Hospital Augsburg, National University of Singapore (NUS), Beijing Tongren Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Evelina London Children's Hospital, King‘s College London, CEU-San Pablo University and HM-Hospitals School of Medicine, University of Cagliari, Medical University of Silesia (SUM), Istanbul University, Cliniques Universitaires Saint-Luc [Bruxelles], University Medical Center [Utrecht], Helsinki University Central Hospital, University of Helsinki, Odense University Hospital (OUH), Luxembourg Institute of Health (LIH), Universidad Complutense de Madrid = Complutense University of Madrid [Madrid] (UCM), Hospital Sant Joan de Déu [Barcelona], Institut de Recerca Pediàtrica Hospital Sant Joan de Déu [Barcelona, Spain], University of Edinburgh, NHS Foundation Trust [London], The Royal Marsden, Nofer Institute of Occupational Medicine (NIOM), Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], Woolcock Institute of Medical Research [Sydney], The University of Sydney, University of Turin, Mauriziano Umberto I Hospital, Humanitas University [Milan] (Hunimed), Vall d'Hebron University Hospital [Barcelona], Hospital de Dona Estefania, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Federal University of Bahia School of Medicine, Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Medical Consulting Czarlewski, Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, MEDIDA, Lda, David Tvildiani Medical University (DTMU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Barlicki University Hospital, Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], Pantai Hospital [Kuala Lumpur], Hospital CUF Descobertas, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Epidemiología y Salud Pública (CIBERESP), Johns Hopkins University School of Medicine [Baltimore], Fukujuji Hospital, Tokyo National Hospital, Chiba Rosai Hospital, Chiba University Hospital, Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, 'Santa Maria della Speranza' Hospital, Centro Hospitalar e Universitário [Coimbra], Coimbra Institute for Clinical and Biomedical Research [Coimbra, Portugal] (iCBR - Faculty of Medicine), University of Coimbra [Portugal] (UC), Medical University of Warsaw - Poland, Hvidovre Hospital, University of Copenhagen = Københavns Universitet (UCPH), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Transilvania University of Brasov, Salvy-Córdoba, Nathalie, Department of Dermatology, Allergology and Venereology, and HUS Inflammation Center
- Subjects
0301 basic medicine ,viruses ,Eaaci Position Paper ,Medizin ,Cochrane Library ,GUIDELINES ,FOOD ALLERGY ,allergen immunotherapy ,allergy clinic ,anaphylaxis ,asthma ,clinical trials ,COVID-19 ,Position Paper ,psychological impact ,SARS-CoV-2 ,Allergists ,Health Personnel ,Humans ,Hypersensitivity ,Information Technology ,Patient Care Team ,Triage ,SARS‐CoV‐2 ,DESENSITIZATION ,0302 clinical medicine ,MESH: Patient Care Team ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,HDE ALER ,Pandemic ,Health care ,Immunology and Allergy ,ATOPIC-DERMATITIS ,MESH: COVID-19 ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,allergen immunotherapy (AIT) ,virus diseases ,DRUG HYPERSENSITIVITY REACTIONS ,3. Good health ,INFECTIONS ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Triage ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,Allergen immunotherapy ,medicine.medical_specialty ,MESH: Information Technology ,MESH: Hypersensitivity ,Immunology ,education ,MEDLINE ,DIAGNOSIS ,psychological COVID ,03 medical and health sciences ,MESH: Allergists ,COVID‐19 ,medicine ,MESH: SARS-CoV-2 ,ddc:610 ,RHINOSINUSITIS ,MESH: Humans ,business.industry ,Clinical trial ,Coronavirus ,EXACERBATIONS ,030104 developmental biology ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Family medicine ,3121 General medicine, internal medicine and other clinical medicine ,Position paper ,MESH: Health Personnel ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business - Abstract
BackgroundThe Coronavirus disease 2019 (COVID‐19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS‐CoV‐2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics.MethodThe scientific information on COVID‐19 was analyzed by a literature search in Medline, Pubmed, national and international guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library and the Internet.ResultsBased on diagnostic and treatment standards developed by EAACI, on international information regarding COVID‐19, on guidelines of the World Health Organization (WHO) and other international organizations as well as on previous experience, a panel of experts including clinicians, psychologists, IT experts and basic scientists along with EAACI and the “Allergic Rhinitis and its Impact on Asthma (ARIA)” inititiative have developed recommendations for the optimal management of allergy clinics during the current COVID‐19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies.ConclusionsThis international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients whilst ensuring necessary safety in the current COVID‐19 pandemic.
- Published
- 2021
- Full Text
- View/download PDF
3. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA
- Author
-
Jere Reijula, De Yun Wang, Ralph Mösges, Tomohisa Iinuma, Jean Luc Fauquert, Nelson Rosario, Yehia El-Gamal, René Maximiliano Gómez, Tari Haahtela, Vincenzo Patella, Lorenzo Cecchi, Petr Panzner, Yoshitaka Okamoto, Oliver Pfaar, Luis Caraballo, Paulo Augusto Moreira Camargos, Filip Raciborski, Florin Mihaltan, Ken Ohta, Brian J. Lipworth, Kimi Okubo, Juan Carlos Ivancevich, Fulvio Braido, Ioana Agache, Frederico S. Regateiro, Neven Miculinic, Tuula Vasankari, R. Emuzyte, Arunas Valiulis, Yousser Mohammad, Torsten Zuberbier, Osman M. Yusuf, Ewa Jassem, Cezmi A. Akdis, Jean Bousquet, Alessandro Fiocchi, Jan Hagemann, Claus Bachert, Davor Plavec, K. S. Bennoor, Marek Jutel, Désirée Larenas-Linnemann, Stephen Montefort, Stefano Del Giacco, Przemyslaw Kardas, Erkka Valovirta, Mark S. Dykewicz, Antonio Valero, Wienczyslawa Czarlewski, Thomas B. Casale, Gabrielle L. Onorato, Omer Kalayci, Ludger Klimek, Joaquin Sastre, João Fonseca, Siân Williams, Karl Christian Bergmann, Marek Niedoszytko, Bilun Gemicioglu, Mario E. Zernotti, Musa Khaitov, H. Neffen, Robert M. Naclerio, Joaquim Mullol, Ana Pereira, Piotr Kuna, Michael Makris, Maria Teresa Ventura, Ioanna Tsiligianni, Dirceu Solé, Arzu Yorgancioglu, Charlotte Suppli-Ulrik, M. Gotua, Emmanuel P. Prokopakis, Dana Wallace, Jorge Maspero, Wytske Fokkens, Eckard Hamelmann, Antonino Romano, Dejan Dokic, Todor A. Popov, Violeta Kvedariene, Derek K. Chu, Anna Bedbrook, Dermot Ryan, Motohiro Ebisawa, Tomas Chivato, Giovanni Passalacqua, Menachem Rottem, Mário Morais-Almeida, Victoria Cardona, Bolesław Samoliński, Cristiana Stellato, Nikolaos G. Papadopoulos, Milan Sova, Jaime Correia-de-Sousa, Sietze Reitsma, Cemal Cingi, Francesca Puggioni, Robyn E O'Hehir, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, HUS Internal Medicine and Rehabilitation, Department of Public Health, Clinicum, Keuhkosairauksien yksikkö, Helsinki University Hospital Area, University of Helsinki, University Medical Center of the Johannes Gutenberg-University Mainz, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Wrocław [Poland] (UWr), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Transilvania University of Brasov, Humboldt University Of Berlin, Medical Consulting Czarlewski, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MASK-air, Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], National Institute of Diseases of the Chest and Hospital (NIDCH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ospedale Policlinico San Martino [Genoa], Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), University of Cartagena, Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Vall d'Hebron University Hospital [Barcelona], Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], CEU-San Pablo University and HM-Hospitals School of Medicine, McMaster University [Hamilton, Ontario], Eskisehir Osmangazi University, Universidade do Minho = University of Minho [Braga], Life and Health Sciences Research Institute [Braga] (ICVS), University of Minho [Braga], The International Primary Care Respiratory Group (IPCRG), Università degli Studi di Cagliari = University of Cagliari (UniCa), Sts. Cyril and Methodius University, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Vilnius University [Vilnius], Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Bambino Gesù Children’s Hospital [Rome, Italy], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, CUF Porto Hospital, Cerrahpasa Faculty of Medicine, Istanbul University, ALAS Medical Institute, Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universität Bielefeld = Bielefeld University, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Medical University of Gdańsk, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Medical University of Łódź (MUL), Federal Medicobiological Agency [Moscow, Russian Federation], Hospital Medica Sur [Mexico City, Mexico], Ninewells Hospital and Medical School [Dundee], University General Hospital ' Attikon ' [Athens, Greece], Argentine Association of Allergy and Immunology, Marius Nasta Institute of Pneumology, Tishreen University, Université de Damas = Damascus University, University of Malta [Malta], Hospital CUF Descobertas, Clinical Research International Ltd [Hamburg, Germany] (CRI), Johns Hopkins University School of Medicine [Baltimore], Nemours/Alfred I. du Pont Hospital for Children, Monash University [Melbourne], Tokyo National Hospital, Nippon Medical School [Tokyo, Japon], Medicine Charles University and General Faculty Hospital in Prague, Royal Manchester Children's Hospital, University of Manchester [Manchester], Università degli studi di Genova = University of Genoa (UniGe), 'Santa Maria della Speranza' Hospital, Philipps Universität Marburg = Philipps University of Marburg, J.J. Strossmayer University of Osijek, Children’s Hospital Srebrnjak [Zagreb, Croatia], St. Ivan Rilski University Hospital, University of Crete [Heraklion] (UOC), IRCCS Humanitas [Rozzano, Italy], Medical University of Warsaw - Poland, Centro Hospitalar e Universitário [Coimbra], Amsterdam UMC - Amsterdam University Medical Center, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Clinica G.B. Morgagni (Fondazione Mediterranea), Pontifical Catholic University of Paraná (PUCPR), Pontifícia Universidade Católica do Paraná (PUCPR), Ha’Emek Medical Center [Afula, Israel], Pediatric Endocrine Institute [Afula, Israel], Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Edinburgh, Federal University of Sao Paulo (Unifesp), University Hospital Olomouc [Czech Republic], University of Salerno (UNISA), Copenhagen University Hospital, Universitat de Barcelona (UB), European Academy of Paediatrics (EAP/UEMS-SP), University of Turku, Suomen Terveystalo Allergy Clinic, Finnish Lung Health Association, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Nova Southeastern University (NSU), Yong Loo Lin School of Medicine [Singapore], Department of Biology, Faculty of Sciences & Liberal Arts, Celal Bayar University, Manisa Celal Bayar University, The Allergy & Asthma Institute, Pakistan (IPCRG), Universidad Nacional de Villa María, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Allergiezentrum Wiesbaden, Salvy-Córdoba, Nathalie, Ear, Nose and Throat, and AII - Inflammatory diseases
- Subjects
0301 basic medicine ,Allergy ,MESH: Asthma ,Common Cold ,allergic rhinitis ,common cold ,cough ,COVID-19 ,smell ,Consensus ,Humans ,SARS-CoV-2 ,Asthma ,Rhinitis, Allergic ,Disease ,Care ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Immunology and Allergy ,MESH: COVID-19 ,Rhinitis ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Common cold ,3. Good health ,MESH: Rhinitis, Allergic ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Original Article ,medicine.symptom ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Immunology ,Signs and symptoms ,Asymptomatic ,03 medical and health sciences ,Allergic ,COVID‐19 ,Internal medicine ,medicine ,MESH: SARS-CoV-2 ,MESH: Consensus ,MESH: Humans ,business.industry ,Rhinitis, Sinusitis, and Upper Airway Disease ,CARE ,medicine.disease ,030104 developmental biology ,030228 respiratory system ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,3121 General medicine, internal medicine and other clinical medicine ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,ORIGINAL ARTICLES ,Airway ,business ,MESH: Common Cold - Abstract
Background Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001). Conclusions This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.
- Published
- 2021
- Full Text
- View/download PDF
4. Next-generation ARIA care pathways for rhinitis and asthma: A model for multimorbid chronic diseases
- Author
-
Bousquet, J.J. and Schünemann, H.J. and Togias, A. and Erhola, M. and Hellings, P.W. and Zuberbier, T. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bachert, C. and Becker, S. and Bedolla-Barajas, M. and Bewick, M. and Bosnic-Anticevich, S. and Bosse, I. and Boulet, L.P. and Bourrez, J.M. and Brusselle, G. and Chavannes, N. and Costa, E. and Cruz, A.A. and Czarlewski, W. and Fokkens, W.J. and Fonseca, J.A. and Gaga, M. and Haahtela, T. and Illario, M. and Klimek, L. and Kuna, P. and Kvedariene, V. and Le, L.T.T. and Larenas-Linnemann, D. and Laune, D. and Lourenço, O.M. and Menditto, E. and Mullol, J. and Okamoto, Y. and Papadopoulos, N. and Pham-Thi, N. and Picard, R. and Pinnock, H. and Roche, N. and Roller-Wirnsberger, R.E. and Rolland, C. and Samolinski, B. and Sheikh, A. and Toppila-Salmi, S. and Tsiligianni, I. and Valiulis, A. and Valovirta, E. and Vasankari, T. and Ventura, M.-T. and Walker, S. and Williams, S. and Akdis, C.A. and Annesi-Maesano, I. and Arnavielhe, S. and Basagana, X. and Bateman, E. and Bedbrook, A. and Bennoor, K.S. and Benveniste, S. and Bergmann, K.C. and Bialek, S. and Billo, N. and Bindslev-Jensen, C. and Bjermer, L. and Blain, H. and Bonini, M. and Bonniaud, P. and Bouchard, J. and Briedis, V. and Brightling, C.E. and Brozek, J. and Buhl, R. and Buonaiuto, R. and Canonica, G.W. and Cardona, V. and Carriazo, A.M. and Carr, W. and Cartier, C. and Casale, T. and Cecchi, L. and Cepeda Sarabia, A.M. and Chkhartishvili, E. and Chu, D.K. and Cingi, C. and Colgan, E. and De Sousa, J.C. and Courbis, A.L. and Custovic, A. and Cvetkosvki, B. and Damato, G. and Da Silva, J. and Dantas, C. and Dokic, D. and Dauvilliers, Y. and Dedeu, A. and De Feo, G. and Devillier, P. and Di Capua, S. and Dykewickz, M. and Dubakiene, R. and Ebisawa, M. and El-Gamal, Y. and Eller, E. and Emuzyte, R. and Farrell, J. and Fink-Wagner, A. and Fiocchi, A. and Fontaine, J.F. and Gemicioǧlu, B. and Schmid-Grendelmeir, P. and Gamkrelidze, A. and Garcia-Aymerich, J. and Gomez, M. and Diaz, S.G. and Gotua, M. and Guldemond, N.A. and Guzmán, M.-A. and Hajjam, J. and O'Hourihane, J.B. and Humbert, M. and Iaccarino, G. and Ierodiakonou, D. and Ivancevich, J.C. and Joos, G. and Jung, K.-S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kardas, P. and Keil, T. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kritikos, V. and Kull, I. and Leonardini, L. and Lieberman, P. and Lipworth, B. and Lodrup Carlsen, K.C. and Loureiro, C.C. and Louis, R. and Mair, A. and Marien, G. and Mahboub, B. and Malva, J. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Mathieu-Dupas, E. and Matricardi, P.M. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.-D. and Mohammad, Y. and Montefort, S. and Monti, R. and Morais-Almeida, M. and Mösges, R. and Münter, L. and Muraro, A. and Murray, R. and Naclerio, R. and Napoli, L. and Namazova-Baranova, L. and Neffen, H. and Nekam, K. and Neou, A. and Novellino, E. and Nyembue, D. and O'Hehir, R. and Ohta, K. and Okubo, K. and Onorato, G. and Ouedraogo, S. and Pali-Schöll, I. and Palkonen, S. and Panzner, P. and Park, H.-S. and Pépin, J.-L. and Pereira, A.-M. and Pfaar, O. and Paulino, E. and Phillips, J. and Plavec, D. and Popov, T.A. and Portejoie, F. and Price, D. and Prokopakis, E.P. and Pugin, B. and Raciborski, F. and Rajabian-Söderlund, R. and Reitsma, S. and Rodo, X. and Romano, A. and Rosario, N. and Rottem, M. and Ryan, D. and Salimäki, J. and Sanchez-Borges, M.M. and Sisul, J.-C. and Solé, D. and Somekh, D. and Sooronbaev, T. and Sova, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Ulrik, C.S. and Thibaudon, M. and To, T. and Todo-Bom, A. and Tomazic, P.V. and Valero, A.A. and Valenta, R. and Valentin-Rostan, M. and Van Der Kleij, R. and Vandenplas, O. and Vezzani, G. and Viart, F. and Viegi, G. and Wallace, D. and Wagenmann, M. and Wang, D.Y. and Waserman, S. and Wickman, M. and Williams, D.M. and Wong, G. and Wroczynski, P. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zeng, S. and Zernotti, M. and Zhang, L. and Zhong, N.S. and Zidarn, M., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHU, Montpellier Cedex 5, 34295, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny Le Bretonneux, France, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Humboldt-Uniersität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Comprehensive Allergy-Centre, Berlin Institute of Health, Berlin, Germany, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, United States, National Institute for Health and Welfare, Helsinki, Finland, Dept. of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, Dept. of Otolaryngology, Head and Neck Surgery, University of Mainz, Mainz, Germany, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, iQ4U Consultants Ltd., London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia, Woolcock Emphysema Centre, Sydney, Australia, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada, EIT Health France, Paris, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, UCIBIO, REQUINTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Levallois, France, Department of Otorhino-Laryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Portugal, Athens Chest Hospital, 7th Resp. Med. Dept. and Asthma Center, Athens, Greece, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Łódź, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, Faculty of Health Sciences and CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, CIRFF, Federico II University, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital P and A Kyriakou, University of Athens, Athens, Greece, Allergy Department, Pasteur Institute, Paris, France, Conseil General de l'Economie Ministere de l'Economie, de l'Industrie et du Numerique, Paris, France, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Pneumologie et Soins Intensifs Respiratoires, Hôpitaux Universitaires Paris, Centre Hôpital Cochin, Paris, France, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Association Asthme et Allergie, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius University, Faculty of Medicine, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo Allergy Clinic, Turku, Finland, FILHA, Finnish Lung Association, Helsinki, Finland, Unit of Geriatric Immunoallergol-ogy, University of Bari Medical School, Bari, Italy, Asthma UK, Mansell Street, London, United Kingdom, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Medicine, University of Cape Town, Cape Town, South Africa, Dept. of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy, Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Global Alliance Against Chronic Respiratory Diseases (WHO GARD), Joensuu, Finland, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Termofscher Scientific, Uppsala, Sweden, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University hospital, Montpellier, France, EA 2991 Euromov, University Montpellier, Montpellier, France, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital, Imperial College, London, United Kingdom, CHU, Dijon, France, Clinical Medicine, Laval's University, Quebec City, Canada, Medicine Department, Hôpital de la Malbaie, Quebec city, QC, Canada, Department of Clinical Pharmacy of Lithuanian, University of Health, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Municipality Pharmacy, Sarno, Italy, Personalized Medicine Clinic Asthma and Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron, ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalu-sia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia, SLaai, Sociedad Lati-noamericana de Allergia, Asma e Immunologia, Barranquilla, Colombia, Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia, Medical Faculty, ENT Department, Eskisehir Osmangazi University, Eskisehir, Turkey, Department of Health, Social Services and Public Safety, Belfast, Northern Ireland, United Kingdom, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, PT Government Associate Laboratory, ICVS/3B's, Braga/Guimarães, Portugal, Ecole des Mines, Alès, France, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, University Hospital of South Manchester, Manchester, United Kingdom, Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital A. Cardarelli, Naples, Italy, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Cáritas Diocesana de Coimbra, Coimbra, Portugal, Ageing at Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical Faculty Skopje, University Clinic of Pulmonology and Allergy, Skopje, North Macedonia, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, Montpellier, France, AQuAS, Barcelna, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Department of Medicine, Surgery and Dentistry Scuola Medica Salernitana, University of Salerno, Salerno, Italy, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania, Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine, Bambino Gesù Children's Research Hospital Holy See, Rome, Italy, Reims, France, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy and Asthma Unit, Hospital San Bernardo Salta, Salta, Argentina, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Centich: Centre d'Expertise National des Technologies de l'Information et de la Communication pour l'Autonomie, Gérontopôle Autonomie Longévité des Pays de la Loire, Conseil Régional des Pays de la Loire, Centre d'Expertise Partenariat Europeen d'Innovation pour un Vieillissement Actif et en Bonne Sante, Nantes, France, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR-S999, Le Kremlin Bicêtre, France, Department of Medicine and Surgery, University of Salerno, Baronissi, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Gyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, First Department of Family Medicine, Medical University of Lodz, Łódź, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Würzburg, Germany, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular Immunology, Moscow, Russian Federation, GARD, Geneva, Switzerland, Allergy and Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Łódź, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Sach's Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Mattone Internazionale Program, Veneto Region, Italy, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, Dundee, United Kingdom, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Pulmonary Medicine, CHU Sart-Tilman, GIGA I3 Research Group, Liege, Belgium, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, Department of Pediatric Pneumology and Immunology, AG Molecular Allergology and Immunomodulation, Charité Medical University, Berlin, Germany, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, PhyMedExp, INSERM U1046, CNRS, UMR 9214, Montpellier, France, Croatian Pulmonary Society, Zagreb, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Turin, Italy, Mexico City, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Syrian Private University, Damascus, Syrian Arab Republic, Faculty of Medicine and Surgery, University of Medicine, La Valette, Malta, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino, Mauriziano Hospital, Turin, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, MedScript Ltd., Paraparomu, New Zealand, OPC, Cambridge, United Kingdom, Johns Hopkins School of Medicine, Baltimore, MD, United States, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Scientific Centre of Children's Health under the Russian Academy of Medical Sciences, Moscow, Russian Federation, Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina, Center for Allergy and Immunology, Santa Fe, Argentina, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar Study Center, Berlin, Germany, Department of Pharmacy, University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Democratic Republic Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Dept. of Otolaryngology, Nippon Medical School, Tokyo, Japan, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept. of Comparative Medicine, Messerli Research Institute, University of Veterinary Medicine and Medical University, Vienna, Austria, EFA European Federation of Allergy and Airways Diseases Patients' Associations, Brussels, Belgium, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Laboratoire HP2, Université Grenoble Alpes, Grenoble, France, INSERM, U1042, CHU de Grenoble, Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Porto, Portugal, Center for Research in Health Technologies and Information Systems, CINTESIS, Universidade do Porto, Porto, Portugal, Maladies Infectieuses et immunitaires, CHUL, Quebec City, QC, Canada, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Farmacias Holon, Lisbon, Portugal, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, Croatia, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital 'Sv Ivan Rilski', Sofia, Bulgaria, Academic Centre of Primary Care, University of Aberdeen, Aberdeen, United Kingdom, Research in Real-Life, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, Rome, Italy, IRCCS Oasi Maria SS, Troina, Italy, Hospital de Clinicas, University of Parana, Paraná, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Allergy and Respiratory Research Group, University of Edinburgh, Edinburgh, United Kingdom, Association of Finnish Pharmacists, Helsinki, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Sociedad Paraguaya de Alergia Asma e Inmunologia, Asunción, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, United Kingdom, Kyrgyzstan National Centre of Cardiology and Internal Medicine, Euro-Asian Respiratory Society, Bishkek, Kyrgyzstan, Department of Respiratory Medicine, University Hospital Olomouc, Olomouc, Czech Republic, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Department of Respiratory Medicine, Hvidovre Hospital and University of Copenhagen, Copenhagen, Denmark, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Sidkkids Hospitala and Institute of Health Policy, Management and Evaluation, Toronto, Canada, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department, CIBERES and Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, NRC Institute of Immunology FMBA of Russia, Moscow, Russian Federation, Laboratory of Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russian Federation, Montevideo, Uruguay, Department of Public Health and Primary Care, Leiden University Medical Center (LUMC), Leiden, Netherlands, Department of Obstetrics and Gynaecology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Reggio Emilia, Italy, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology A Monroy, Palermo, Italy, Nova Southeastern University, Fort Lauderdale, FL, United States, Dept. of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Düsseldorf, Germany, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Cyprus International Institute for Environmental, Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital Archbishop Makarios III, Nicosia, Cyprus, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's Hospital, Cape Town, South Africa, MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa, Bull DSAS, Echirolles, France, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, and National Hospital Organization, Tokyo National Hospital, Tokyo, Japan
- Abstract
Background: In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body: As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhi-nitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted "patient activation", (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion: In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement. © The Author(s) 2019.
- Published
- 2019
5. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy': AIRWAYS ICPs initiative (European Innovation Partnership on Active and Healthy Ageing, DG CONNECT and DG Santé) POLLAR (Impact of Air POLLution on Asthma and Rhinitis) GARD Demonstration project
- Author
-
Bosnic-Anticevich, S. and Costa, E. and Menditto, E. and Lourenço, O. and Novellino, E. and Bialek, S. and Briedis, V. and Buonaiuto, R. and Chrystyn, H. and Cvetkovski, B. and Di Capua, S. and Kritikos, V. and Mair, A. and Orlando, V. and Paulino, E. and Salimäki, J. and Söderlund, R. and Tan, R. and Williams, D.M. and Wroczynski, P. and Agache, I. and Ansotegui, I.J. and Anto, J.M. and Bedbrook, A. and Bachert, C. and Bewick, M. and Bindslev-Jensen, C. and Brozek, J.L. and Canonica, G.W. and Cardona, V. and Carr, W. and Casale, T.B. and Chavannes, N.H. and Correia de Sousa, J. and Cruz, A.A. and Czarlewski, W. and De Carlo, G. and Demoly, P. and Devillier, P. and Dykewicz, M.S. and Gaga, M. and El-Gamal, Y. and Fonseca, J. and Fokkens, W.J. and Guzmán, M.A. and Haahtela, T. and Hellings, P.W. and Illario, M. and Ivancevich, J.C. and Just, J. and Kaidashev, I. and Khaitov, M. and Khaltaev, N. and Keil, T. and Klimek, L. and Kowalski, M.L. and Kuna, P. and Kvedariene, V. and Larenas-Linnemann, D.E. and Laune, D. and Le, L.T.T. and Lodrup Carlsen, K.C. and Mahboub, B. and Maier, D. and Malva, J. and Manning, P.J. and Morais-Almeida, M. and Mösges, R. and Mullol, J. and Münter, L. and Murray, R. and Naclerio, R. and Namazova-Baranova, L. and Nekam, K. and Nyembue, T.D. and Okubo, K. and O'Hehir, R.E. and Ohta, K. and Okamoto, Y. and Onorato, G.L. and Palkonen, S. and Panzner, P. and Papadopoulos, N.G. and Park, H.-S. and Pawankar, R. and Pfaar, O. and Phillips, J. and Plavec, D. and Popov, T.A. and Potter, P.C. and Prokopakis, E.P. and Roller-Wirnsberger, R.E. and Rottem, M. and Ryan, D. and Samolinski, B. and Sanchez-Borges, M. and Schunemann, H.J. and Sheikh, A. and Sisul, J.C. and Somekh, D. and Stellato, C. and To, T. and Todo-Bom, A.M. and Tomazic, P.V. and Toppila-Salmi, S. and Valero, A. and Valiulis, A. and Valovirta, E. and Ventura, M.T. and Wagenmann, M. and Wallace, D. and Waserman, S. and Wickman, M. and Yiallouros, P.K. and Yorgancioglu, A. and Yusuf, O.M. and Zar, H.J. and Zernotti, M.E. and Zhang, L. and Zidarn, M. and Zuberbier, T. and Bousquet, J., Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, UCIBIO, REQUIMTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, CIRFF, Federico II University, Naples, Italy, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Department of Pharmacy of University of Naples Federico II, Naples, Italy, Department of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Department of Clinical Pharmacy of Lithuanian, University of Health Sciences, Kaunas, Lithuania, Pharmacist, Municipality Pharmacy, Sarno, Italy, RiRL, Oakington, Cambridge, United Kingdom, Farmacie Dei Golfi Group, Massa Lubrense, Italy, DG for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Farmacias Holon, Lisbon, Portugal, Association of Finnish Pharmacies, Helsinki, Finland, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, Transylvania University Brasov, Brasov, Romania, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, MACVIA-France, Fondation Partenariale FMC VIA-LR, Montpellier, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, iQ4U Consultants Ltd, London, United Kingdom, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Personalized Medicine Clinic Asthma & Allergy, Humanitas Research Hospital, Humanitas University, Rozzano, Milan, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall ‘dHebron & ARADyAL Research Network, Barcelona, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil, WHO GARD Planning Group, Brasilia, Brazil, Medical Consulting Czarlewski, Levallois, France, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, Medical School Saint Antoine, INSERM and UPMC Sorbonne Université, Paris, France, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Université Paris Saclay, Saclay, France, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, ERS President 2017-2018, Athens Chest Hospital, 7th Resp Med Department and Asthma Center, Athens, Greece, Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, MEDIDA, Lda, Porto, Portugal, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, University of Helsinki, Helsinki, Finland, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Ukrainian Medical Stomatological Academy, Poltava, Ukraine, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation, GARD Chairman, Geneva, Switzerland, Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany, Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Department of Paediatrics, Oslo University Hospital, Oslo, Norway, Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Biomax Informatics AG, Munich, Germany, Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, MedScript Ltd, Dundalk, Co Louth, Ireland, Johns Hopkins School of Medicine, Baltimore, MD, United States, Scientific Centre of Children's Health under the MoH, Russia, Russian National Research Medical University named Pirogov, Moscow, Russian Federation, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, ENT Department, University Hospital of Kinshasa, Kinshasa, Congo, Department of Otolaryngology, Nippon Medical School, Tokyo, Japan, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, National Hospital Organization Tokyo National Hospital, Tokyo, Japan, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Section for Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany, Centre for Empowering Patients and Communities, Faulkland, Somerset, United Kingdom, Children's Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, University Hospital ‘Sv Ivan Rilski’', Sofia, Bulgaria, Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Past President SLAAI, FACAAI, Edinburgh, United Kingdom, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Médico-Docente la Trinidad, Caracas, Trinidad, Trinidad and Tobago, Clínica El Avila, Altamira, Caracas, Venezuela, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Sociedad Paraguaya de Alergia Asma e Inmunologie, Asuncion, Paraguay, European Health Futures Forum (EHFF), Isle of Wright, United Kingdom, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, Imunoalergologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal, Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Department of ENT, Medical University of Graz, Graz, Austria, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Clinic of Children's Diseases and Institute of Health Sciences, Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Dusseldorf, Germany, Nova Southeastern University, Fort Lauderdale, FL, United States, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Cyprus International Institute for Environmenta & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital 'Archbishop Makarios III', Nicosia, Cyprus, Department of Pulmonology, Celal Bayar University, Manisa, Turkey, The Allergy and Asthma Institute, Islamabad, Pakistan, Department of Paediatrics and Child Health, Red Cross Children's, Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Beijing Institute of Otolaryngology, Beijing, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Comprehensive Allergy Center, A member of GA2LEN, Berlin, Germany, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, and Euforea, Brussels, Belgium
- Subjects
humanities - Abstract
Pharmacists are trusted health care professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact for allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The Allergic Rhinitis and its Impact on Asthma (ARIA)-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses), and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of allergic rhinitis. However, the ARIA-pharmacy ICP should be adapted to local healthcare environments/situations as regional (national) differences exist in pharmacy care. © 2018 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2019
6. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
- Author
-
Piotr Kuna, J. C. Ivancevich, Dana Wallace, Alvaro A. Cruz, Igor Kaidashev, Louis-Philippe Boulet, Anna Bedbrook, Marek L. Kowalski, Ioana Agache, Hae-Sim Park, Gregoire Mercier, Mario Sánchez-Borges, Karl-Christian Bergmann, Tomohisa Iinuma, Peter Hellings, Graham Roberts, Erkka Valovirta, Antonella Muraro, Robyn E O'Hehir, Oliver Pfaar, Luis Caraballo, Mohamed H. Shamji, Torsten Zuberbier, Guy Brusselle, Nicolas Roche, Dermot Ryan, Holger J. Schünemann, Ignacio J. Ansotegui, Erik Melén, V. Cardona, Wienczyslawa Czarlewski, Mike Bewick, Ana-Maria Todo Bom, Susan Waserman, Sinthia Bosnic-Anticevich, Ludger Klimek, Isabelle Bosse, Sanna Toppila-Salmi, Giovanni Passalacqua, Daniel Laune, Lan Le, Despo Ierodiakonou, Gert Marien, Derek K. Chu, Akdis Togias, M. T. Ventura, Marek Jutel, Désirée Larenas-Linnemann, João Fonseca, Elísio Costa, Motohiro Ebisawa, Mark S. Dykewicz, Roy Gerth van Wijk, Musa Khaitov, Pedro Carreiro-Martins, Ioana Tsiligianni, Ettore Novellino, Wytske Fokkens, Nelson Rosario, Thomas B. Casale, Philippe Bonniaud, Bolesław Samoliński, Omer Kalayci, Olga Lourenço, Yoshitaka Okamoto, Moises A. Calderon, Stefania La Grutta, Gennaro D'Amato, Glenis Scadding, Bilun Gemicioglu, Petr Panzner, Philippe Devillier, Ralph Mosgues, Susanne Halken, Susanne Lau, Violeta Kvedariene, Aziz Sheikh, Samantha Walker, Marylin Valentin-Rostan, Martina Erhola, Nhan Pham-Thi, Christine Rolland, H. Neffen, Jean Bousquet, Jean-François Fontaine, Jacques Bouchard, Jean-Louis Fauquert, Arunas Valiulis, Claus Bachert, Lorenzo Cecchi, Jorg Kleine Tebbe, Walter Canonica, David Price, Tari Haahtela, Ken Ohta, Philipp Lieberman, Leyla Namazova, Karin C. Lødrup Carlsen, Joaquim Mullol, Enrica Menditto, Arzu Yorgancioglu, Jan Brozek, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Humboldt-Universität zu Berlin, McMaster University [Hamilton, Ontario], National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), Upper Airways Research Laboratory, Universiteit Gent = Ghent University [Belgium] (UGENT), National Institute for Health and Welfare [Helsinki], University Hospitals Leuven [Leuven], VU University Medical Center [Amsterdam], Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Philipps Universität Marburg, Nova Southeastern University (NSU), Hospital Quirónsalud Bizkaia [Bilbao], Transilvania University of Brasov, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], iQ4U consultants Ltd, CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Allergist [La Rochelle], Laval University Medical center, Université Laval [Québec] (ULaval), Quebec Heart and Lung Institute, Ghent University Hospital, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Humanitas University [Milan] (Hunimed), Institute for Immunological Research (University of Cartagena), Vall d'Hebron University Hospital [Barcelona], RETIC ARADyAL, University of South Florida [Tampa] (USF), SOS Allergology and Clinical Immunology, Unidade de Ciencias Biomoleculares Aplicadas (UCIBIO), Requimte, Departamento de Química (DQ), Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Faculdade de Ciências e Tecnologia = School of Science & Technology (FCT NOVA), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto, ProAR – Nucleo de Excelencia em Asma, Universidade Federal da Bahia (UFBA), Medical Consulting Czarlewski, 'Federico II' University of Naples Medical School, Laboratoire de Pharmacologie Respiratoire UPRES EA220, UPRES EA 220, Pôle des maladies respiratoires, Hôpital Foch, Washington University School of Medecine [Saint Louis, MO], Sagamihara National Hospital, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, Department of Otorhinolaryngology [Amsterdam], Academic Medical Centre [Amsterdam], University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Allergist [Reims], Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Skin and allergy hospital [Helsinki, Finland], Odense University Hospital [Odense, Denmark], University General Hospital of Heraklion, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Wroclaw Medical University [Wrocław, Pologne], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], Hacettepe University School of Medicine, DRK Kliniken Berlin, Westend, Medical University of Łódź (MUL), Barlicki University Hospital, Vilnius University [Vilnius], Institute of Biomedicine and Molecular Immunology (IBIM), Hospital Medica Sur [Mexico City, Mexico], KYomed INNOV [Montpellier], Ho Chi Minh City University of Medicine, The University of Tennessee Health Science Center [Memphis] (UTHSC), Oslo University Hospital [Oslo], University of Beira Interior [Portugal] (UBI), Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Sachs’ Children and Youth Hospital [Stockholm, Sweden], Karolinska Institutet [Stockholm], Center for Allergy and Immunology and Respiratory Diseases, Département d'Information Médicale [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University Hospital of Cologne [Cologne], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), University Hospital of Padua, Pirogov Russian National Research Medical University [Moscow, Russia], Monash University [Melbourne], Tokyo National Hospital, Ajou University, Charles University [Prague] (CU), Ospedale Policlinico San Martino [Genoa], Centre Médical de l'Institut Pasteur, Institut Pasteur [Paris], Observational and Pragmatic Research Institute, Singapore, Singapore, The David Hide Asthma and Allergy Research Centre, St Mary's Hospital-University Hospital Southampton NHS Foundation Trust, Département des maladies respiratoires [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Association Asthme et Allergies, Universidade Federal do Parana [Curitiba] (UFPR), Universidade Federal do Paraná (UFPR), University of Edinburgh, Medical University of Warsaw - Poland, Centro Médico Docente La Trinidad, The Royal National TNE Hospital, University College of London [London] (UCL), Imperial College London, Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Coimbra [Portugal] (UC), University of Helsinki, University of Crete [Heraklion] (UOC), Allergist, University of Turku, Terveystalo Pulssi, University of Bari Aldo Moro (UNIBA), Asthma UK Centre in Allergic Mechanisms of Asthma, King's College London, (MRC), Guy's Hospital [London], Manisa Celal Bayar University, uBibliorum, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Humboldt University Of Berlin, Universiteit Gent = Ghent University (UGENT), Philipps Universität Marburg = Philipps University of Marburg, Universidade do Porto = University of Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade do Porto = University of Porto-Departamento de Química (DQ), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Washington University School of Medicine [Saint Louis, MO], Sagamihara National Hospital [Kanagawa, Japan], Universidade do Porto = University of Porto, Wrocław Medical University, Azienda Ospedale Università di Padova = Hospital-University of Padua (AOUP), Pirogov Russian National Research Medical University, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Internal Medicine, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade do Porto-Departamento de Química (DQ), and CCSD, Accord Elsevier
- Subjects
MESH: Asthma ,Allergy ,[INFO.INFO-DS] Computer Science [cs]/Data Structures and Algorithms [cs.DS] ,Disease ,Allergic Rhinitis and Its Impact on Asthma ,medicine.disease_cause ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Allergic rhinitis ,Grading of Recommendations Assessment ,law.invention ,0302 clinical medicine ,Allergen ,Randomized controlled trial ,MESH: Practice Guidelines as Topic ,law ,HDE ALER ,HEALTH LITERACY ,Immunology and Allergy ,030212 general & internal medicine ,guidelines ,[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology ,MASK-RHINITIS ,mHealth ,PLACEBO ,LORATADINE ,MOBILE TECHNOLOGY ,3. Good health ,Evidence-Based Practice ,Practice Guidelines as Topic ,MESH: Rhinitis, Allergic ,AZELASTINE NASAL SPRAY ,Life Sciences & Biomedicine ,[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology ,Algorithms ,medicine.medical_specialty ,Evidence-based practice ,Visual analogue scale ,[INFO.INFO-DS]Computer Science [cs]/Data Structures and Algorithms [cs.DS] ,Immunology ,MESH: Algorithms ,MACVIA-ARIA ,03 medical and health sciences ,[SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics ,Pharmacotherapy ,medicine ,Humans ,QUALITY ,Development and Evaluation ,real-world evidence ,Intensive care medicine ,Asthma ,[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics ,MESH: Humans ,Science & Technology ,business.industry ,MESH: Evidence-Based Practice ,medicine.disease ,EFFICACY ,Rhinitis, Allergic ,030228 respiratory system ,ONSET ,[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,business - Abstract
The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY vol:145 issue:1 pages:70-+ ispartof: location:United States status: published
- Published
- 2019
- Full Text
- View/download PDF
7. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
- Author
-
Bousquet, J. and Arnavielhe, S. and Bedbrook, A. and Bewick, M. and Laune, D. and Mathieu-dupas, E. and Murray, R. and Onorato, G.L. and Pépin, J.L. and Picard, R. and Portejoie, F. and Costa, E. and Fonseca, J. and Lourenço, O. and Morais-Almeida, M. and Todo-bom, A. and Cruz, A.A. and Silva, J.D. and Serpa, F.S. and Illario, M. and Menditto, E. and Cecchi, L. and Monti, R. and Napoli, L. and Ventura, M.T. and De Feo, G. and Larenas-linnemann, D. and Fuentes Perez, M. and Huerta Villabolos, Y.R. and Rivero-yeverino, D. and Rodriguez-zagal, E. and Amat, F. and Annesi-maesano, I. and Bosse, I. and Demoly, P. and Devillier, P. and Fontaine, J.F. and Just, J. and Kuna, T.P. and Samolinski, B. and Valiulis, A. and Emuzyte, R. and Kvedariene, V. and Ryan, D. and Sheikh, A. and Schmidt-grendelmeier, P. and Klimek, L. and Pfaar, O. and Bergmann, K.C. and Mösges, R. and Zuberbier, T. and Roller-wirnsberger, R.E. and Tomazic, P. and Fokkens, W.J. and Chavannes, N.H. and Reitsma, S. and Anto, J.M. and Cardona, V. and Dedeu, T. and Mullol, J. and Haahtela, T. and Salimäki, J. and Toppila-Salmi, S. and Valovirta, E. and Gemicioğlu, B. and Yorgancioglu, A. and Papadopoulos, N. and Prokopakis, E.P. and Bosnic-anticevich, S. and O’hehir, R. and Ivancevich, J.C. and Neffen, H. and Zernotti, E. and Kull, I. and Melen, E. and Wickman, M. and Bachert, C. and Hellings, P. and Palkonen, S. and Bindslev-jensen, C. and Eller, E. and Waserman, S. and Sova, M. and De Vries, G. and van Eerd, M. and Agache, I. and Casale, T. and Dykewickz, M. and Naclerio, R.N. and Okamoto, Y. and Wallace, D.V. and Hellings, P.W. and Aberer, W. and Akdis, C.A. and Akdis, M. and Alberti, M.R. and Almeida, R. and Angles, R. and Ansotegui, I.J. and Arnavielle, S. and Asayag, E. and Asarnoj, A. and Arshad, H. and Avolio, F. and Bacci, E. and Baiardini, I. and Barbara, C. and Barbagallo, M. and Baroni, I. and Barreto, B.A. and Basagana, X. and Bateman, E.D. and Bedolla-Barajas, M. and Beghé, B. and Bel, E.H. and Bennoor, K.S. and Benson, M. and Bertorello, L. and Białoszewski, A.Z. and Bieber, T. and Bialek, S. and Bjermer, L. and Blain, H. and Blasi, F. and Blua, A. and Bochenska Marciniak, M. and Bogus-Buczynska, I. and Boner, A.L. and Bonini, M. and Bonini, S. and Bosnic-Anticevich, C.S. and Bouchard, J. and Boulet, L.P. and Bourret, R. and Bousquet, P.J. and Braido, F. and Briedis, V. and Brightling, C.E. and Brozek, J. and Bucca, C. and Buhl, R. and Buonaiuto, R. and Panaitescu, C. and Burguete Cabañas, M.T. and Burte, E. and Bush, A. and Caballero-Fonseca, F. and Caillot, D. and Caimmi, D. and Calderon, M.A. and Camargos, P.A.M. and Camuzat, T. and Canfora, G. and Canonica, G.W. and Carlsen, K.H. and Carreiro-Martins, P. and Carriazo, A.M. and Carr, W. and Cartier, C. and Castellano, G. and Cepeda, A.M. and Chen, Y. and Chiron, R. and Chivato, T. and Chkhartishvili, E. and Chuchalin, A.G. and Chung, K.F. and Ciaravolo, M.M. and Ciceran, A. and Cingi, C. and Ciprandi, G. and Carvalho Coehlo, A.C. and Colas, L. and Colgan, E. and Coll, J. and Conforti, D. and Correia de Sousa, J. and Cortés-Grimaldo, R.M. and Corti, F. and Costa-Dominguez, M.C. and Courbis, A.L. and Cox, L. and Crescenzo, M. and Custovic, A. and Czarlewski, W. and Dahlen, S.E. and Dario, C. and da Silva, J. and Dauvilliers, Y. and Darsow, U. and De Blay, F. and De Carlo, G. and de Fátima Emerson, M. and De Martino, B. and de Paula Motta Rubini, N. and Deleanu, D. and Denburg, J.A. and Di Capua Ercolano, S. and Di Carluccio, N. and Didier, A. and Dokic, D. and Dominguez-Silva, M.G. and Douagui, H. and Dray, G. and Dubakiene, R. and Durham, S.R. and Du Toit, G. and Dykewicz, M.S. and El-Gamal, Y. and Eklund, P. and Farrell, J. and Farsi, A. and Ferreira de Mello, J., Jr. and Ferrero, J. and Fink-Wagner, A. and Fiocchi, A. and Fonseca, J.A. and Forti, S. and Fuentes-Perez, J.M. and Gálvez-Romero, J.L. and Gamkrelidze, A. and Garcia-Aymerich, J. and García-Cobas, C.Y. and Garcia-Cruz, M.H. and Genova, S. and George, C. and Gereda, J.E. and Gerth van Wijk, R. and Gomez, R.M. and Gómez-Vera, J. and González Diaz, S. and Gotua, M. and Grisle, I. and Guidacci, M. and Guldemond, N.A. and Gutter, Z. and Guzmán, M.A. and Hajjam, J. and Hernández, L. and Hourihane, J.O.’.B. and Huerta-Villalobos, Y.R. and Humbert, M. and Iaccarino, G. and Jares, E.J. and Jassem, E. and Johnston, S.L. and Joos, G. and Jung, K.S. and Jutel, M. and Kaidashev, I. and Kalayci, O. and Kalyoncu, A.F. and Karjalainen, J. and Kardas, P. and Keil, T. and Keith, P.K. and Khaitov, M. and Khaltaev, N. and Kleine-Tebbe, J. and Kowalski, M.L. and Kuitunen, M. and Kuna, P. and Kupczyk, M. and Krzych-Fałta, E. and Lacwik, P. and Lauri, D. and Lavrut, J. and Le, L.T.T. and Lessa, M. and Levato, G. and Li, J. and Lieberman, P. and Lipiec, A. and Lipworth, B. and Lodrup Carlsen, K.C. and Louis, R. and Luna-Pech, J.A. and Maciej, K. and Magnan, A. and Mahboub, B. and Maier, D. and Mair, A. and Majer, I. and Malva, J. and Mandajieva, E. and Manning, P. and De Manuel Keenoy, E. and Marshall, G.D. and Masjedi, M.R. and Maspero, J.F. and Matta Campos, J.J. and Matos, A.L. and Maurer, M. and Mavale-Manuel, S. and Mayora, O. and Medina-Avalos, M.A. and Melén, E. and Melo-Gomes, E. and Meltzer, E.O. and Mercier, J. and Miculinic, N. and Mihaltan, F. and Milenkovic, B. and Moda, G. and Mogica-Martinez, M.D. and Mohammad, Y. and Momas, I. and Montefort, S. and Mora Bogado, D. and Morato-Castro, F.F. and Mota-Pinto, A. and Moura Santo, P. and Münter, L. and Muraro, A. and Naclerio, R. and Nadif, R. and Nalin, M. and Namazova-Baranova, L. and Niedeberger, V. and Nekam, K. and Neou, A. and Nieto, A. and Nogueira-Silva, L. and Nogues, M. and Novellino, E. and Nyembue, T.D. and O’hehir, R.E. and Odzhakova, C. and Ohta, K. and Okubo, K. and Ortega Cisneros, M. and Ouedraogo, S. and Pali-Schöll, I. and Panzner, P. and Papadopoulos, N.G. and Park, H.S. and Papi, A. and Passalacqua, G. and Paulino, E. and Pawankar, R. and Pedersen, S. and Pereira, A.M. and Persico, M. and Phillips, J. and Pigearias, B. and Pin, I. and Pitsios, C. and Plavec, D. and Pohl, W. and Popov, T.A. and Potter, P. and Pozzi, A.C. and Price, D. and Puy, R. and Pugin, B. and Pulido Ross, R.E. and Przemecka, M. and Rabe, K.F. and Raciborski, F. and Rajabian-Soderlund, R. and Ribeirinho, I. and Rimmer, J. and Rizzo, J.A. and Rizzo, M.C. and Robalo-Cordeiro, C. and Rodenas, F. and Rodo, X. and Rodriguez Gonzalez, M. and Rodriguez-Mañas, L. and Rolland, C. and Rodrigues Valle, S. and Roman Rodriguez, M. and Romano, A. and Rolla, G. and Romano, M. and Rosado-Pinto, J. and Rosario, N. and Rottem, M. and Sagara, H. and Sanchez-Borges, M. and Sastre-Dominguez, J. and Scadding, G.K. and Schunemann, H.J. and Scichilone, N. and Schmid-Grendelmeier, P. and Shamai, S. and Sierra, M. and Simons, F.E.R. and Siroux, V. and Sisul, J.C. and Skrindo, I. and Solé, D. and Somekh, D. and Sondermann, M. and Sooronbaev, T. and Sorensen, M. and Sorlini, M. and Spranger, O. and Stellato, C. and Stelmach, R. and Stukas, R. and Sunyer, J. and Strozek, J. and Szylling, A. and Tebyriçá, J.N. and Thibaudon, M. and To, T. and Tomazic, P.V. and Trama, U. and Triggiani, M. and Suppli Ulrik, C. and Urrutia-Pereira, M. and Valenta, R. and Valero, A. and van Ganse, E. and van Hague, M. and Vandenplas, O. and Vezzani, G. and Vasankari, T. and Vatrella, A. and Verissimo, M.T. and Viart, F. and Viegi, G. and Vicheva, D. and Vontetsianos, T. and Wagenmann, M. and Walker, S. and Wallace, D. and Wang, D.Y. and Werfel, T. and Westman, M. and Williams, D.M. and Williams, S. and Wilson, N. and Wright, J. and Wroczynski, P. and Yakovliev, P. and Yawn, B.P. and Yiallouros, P.K. and Yusuf, O.M. and Zar, H.J. and Zhang, L. and Zhong, N. and Zernotti, M.E. and Zidarn, M. and Zubrinich, C. and Zurkuhlen, A., MACVIA-France, Fondation Partenariale FMC VIA-LR, CHRU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, KYomed-INNOV, Montpellier, France, iQ4U Consultants Ltd, London, United Kingdom, MedScript Ltd, Dundalk, Co Louth, Ireland, Laboratoire HP2, Grenoble, INSERM, U1042, Université Grenoble Alpes, Grenoble, France, CHU de Grenoble, Grenoble, France, Conseil Général de l’Economie Ministère de l’Economie, de l’Industrie et du Numérique, Paris, France, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing, University of Porto (Porto4Ageing), Porto, Portugal, Center for Health Technology and Services Research, - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Vitória da Conquista, Brazil, WHO GARD Planning Group, Salvador, Brazil, Allergy Service, University Hospital of Federal University of Santa Catarina (HU-UFSC), Florianópolis, Brazil, Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria, Vitória, Esperito Santo, Brazil, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, CIRFF, Federico II University, Naples, Italy, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Medical Sciences, Allergy and Clinical Immunology Unit, University of Torino & Mauriziano Hospital, Torino, Italy, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Mexico City, Mexico, Puebla, Puebla, Mexico, Ciutad Mexico, Mexico, Allergology Department, Centre de l’Asthme et des Allergies Hôpital d’Enfants Armand-Trousseau (APHP), Paris, France, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universités, Equipe EPAR, Paris, 75013, France, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, UPMC Sorbonne Université, Medical School Saint Antoine, Paris, France, La Rochelle, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Reims, France, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Clinic of Children’s Diseases, and Institute of Health Sciences Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Woodbrook Medical Centre, Loughborough, United Kingdom, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, United Kingdom, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Allergy Unit, Department of Dermatology, University Hospital of Zurich, Zürich, Switzerland, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Comprehensive Allergy, -Centre, -Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Allergy Section, Department of Internal Medicine, Hospital Vall ‘dHebron & ARADyAL Research Network, Barcelona, Spain, AQuAS, Barcelona, Spain, EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Association of Finnish Pharmacists, Helsinki, Finland, Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland, Terveystalo Allergy Clinic, Turku, Finland, Department of Pulmonary Diseases, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, GARD Executive Committee, Manisa, Turkey, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P&A Kyriakou', University of Athens, Athens, 11527, Greece, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Department of Immunology, Monash University, Melbourne, VIC, Australia, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Director of Center of Allergy, Immunology and Respiratory Diseases, Santa Fe, Argentina Center for Allergy and Immunology, Santa Fe, Argentina, Universidad Católica de Córdoba, Córdoba, Argentina, Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, Univ Hospitals Leuven, Louvain, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, University Hospital Olomouc, Olomouc, Czech Republic, Peercode BV, Geldermalsen, Netherlands, Faculty of Medicine, Transylvania University, Brasov, Romania, Division of Allergy/Immunology, University of South Florida, Tampa, United States, Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, MO, United States, Johns Hopkins School of Medicine, Baltimore, MD, United States, Department of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Nova Southeastern University, Fort Lauderdale, FL, United States, University Hospital, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, VIMA. INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, Department of Dermatology, Medical University of Graz, Graz, Austria, Transylvania University Brasov, Brasov, Romania, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Chairman of the Council of Municipality of Salerno, Italy, Center for Health Technology and Services Research-CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medida, Lda Porto, Portugal, Allergology department, Centre de l’Asthme et des Allergies Hôpital d’Enfants Armand-Trousseau (APHP), Sorbonne Université, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirón Bizkaia, Erandio, Spain, KYomed INNOV, Montpellier, France, Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina, Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, and Astrid Lindgren Children’s Hospital, Department of Pediatric Pulmonology and Allergy, Karolinska University Hospital, Stockholm, Sweden, David Hide Asthma and Allergy Research Centre, Isle of Wight, United Kingdom, Regionie Puglia, Bari, Italy, Regione Liguria, Genoa, Italy, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Allergy and Respiratory Diseases, Ospedale Policlinico San Martino, University of Genoa, Italy, PNDR, Portuguese National Programme for Respiratory Diseases, Faculdade de Medicina de Lisboa, Lisbon, Portugal, Director of the Geriatric Unit, Department of Internal Medicine (DIBIMIS), University of Palermo, Italy, Telbios SRL, Milan, Italy, Universidade do Estado do Pará, Belem, Brazil, Department of Medicine, University of Cape Town, Cape Town, South Africa, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, Section of Respiratory Disease, Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy, Depart-ment of Respiratory Medicine, Academic Medical Center (AMC), University of Amsterdam, Netherlands, Comprehensive Allergy Center Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Deptt of Respiratory Medicine, National Institute of Diseases of the Chest and Hospital, Dhaka, Bangladesh, Centre for Individualized Medicine, Department of Pediatrics, Faculty of Medicine, Linköping, Sweden, Depart-ment of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland, BIEBER. Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany, Dept of Biochemistry and Clinical Chemistry, Faculty of Pharmacy with the Division of Laboratory Medicine, Warsaw Medical University, Warsaw, Poland, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Department of Geriatrics, Montpellier University Hospital, Montpellier, France, EA 2991, Euromov, University Montpellier, France, Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy, Argentine Association of Respiratory Medicine, Buenos Aires, Argentina, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Pediatric Department, University of Verona Hospital, Verona, Italy, Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy, Second University of Naples and Institute of Translational Medicine, Italian National Research Council, Italy, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and and Sydney Local Health District, Glebe, NSW, Australia, Allergist, La Rochelle, France, Associate professor of clinical medecine, Laval’s University, Quebec city, Head of medecine department, Hôpital de la MalbaieQC, Canada, Quebec Heart and Lung Institute, Laval University, Québec City, QC, Canada, Centre Hospitalier Valenciennes, France, Head of Department of Clinical Pharmacy of Lithuanian University of Health Sciences, Kaunas, Lithuania, Institute of Lung Health, Respiratory Biomedical Unit, University Hospitals of Leicester NHS Trust, Leicestershire, United Kingdom, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom, Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Chief of the University Pneumology Unit-AOU Molinette, Hospital City of Health and Science of Torino, Italy, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany, Pharmacist, Municipality Pharmacy, Sarno, Italy, University of Medicine and Pharmacy Victor Babes, Timisoara, Romania, Instituto de Pediatria, Hospital Zambrano Hellion Tec de Monterrey, Monterrey, Mexico, Imperial College and Royal Brompton Hospital, London, United Kingdom, Centro Medico Docente La Trinidad, CaRacas, Venezuela, Regional Director Assofarm Campania and Vice President of the Board of Directors of Cofaser, Salerno, Italy, Service de pneumologie, CHU et université d’Auvergne, Clermont-Ferrand, France, Department of Respiratory Diseases, Montpellier University Hospital, France, Imperial College London-National Heart and Lung Institute, Royal Brompton Hospital NHS, London, United Kingdom, Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil, Assitant Director General, Montpellier, Région Occitanie, France, Mayor of Sarno and President of Salerno Province, Director, Anesthesiology Service, Sarno 'Martiri del Villa Malta' Hospital, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron & ARADyAL Spanish Research Network, Barcelona, Spain, Department of Paediatrics, Oslo University Hospital and University of Oslo, Oslo, Norway, CEDOC, Integrated Pathophysiological Mechanisms Research Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, and Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal, Regional Ministry of Health of Andalusia, Seville, Spain, Allergy and Asthma Associates of Southern California, Mission Viejo, CA, United States, ASA-Advanced Solutions Accelerator, Clapiers, France, Division of Allergy/Immunology, University of South Florida, Tampa, FL, United States, Celentano pharmacy, Massa Lubrense, Italy, Allergy and Immunology Laboratory, Metropolitan University Hospital, Branquilla, Colombia, Capital Institute of Pediatrics, Chaoyang district, Beijing, China, School of Medicine, University CEU San Pablo, Madrid, Spain, David Tvildiani Medical University-AIETI Highest Medical School, David Tatishvili Medical Center Tbilisi, Georgia, Pulmonolory Research Institute FMBA, Moscow, Russian Federation, GARD Executive Committee, Moscow, Russian Federation, National Heart & Lung Institute, Imperial College, London, United Kingdom, Specialist social worker, Sorrento, Italy, Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Medicine Department, IRCCS-Azienda Ospedaliera Universitaria San Martino, Genoa, Italy, Universidade Federal da Bahia, Escola de Enfermagem, Brazil, Plateforme Transversale d’Allergologie, Institut du Thorax, CHU de Nantes, Nantes, France, LANUA International Healthcare Consultancy, Northern Ireland, United Kingdom, Innovation and Research Office, Department of Health and Social Solidarity, Autonomous Province of Trento, Italy, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, ICVS/3B’s, PT Government Associate Laboratory, Braga/Guimarães, Portugal, Guadalarara, Mexico, FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto(Porto4Ageing), Porto, Portugal, IMT Mines Alès, Unversité Montpellier, Alès, France, Department of Medicine, Nova Southeastern University, Davie, University of Miami Dept of Medicine, Miami, FL, United States, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Brazil, Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester and University Hospital of South Manchester, Manchester, United Kingdom, Medical Consulting Czarlewski, Levallois, France, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Italy, Department of Internal Medicine, Federal University of Santa Catarina, Trindade, Florianópolis, Santa Catarina, Brazil, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac Montpellier, Inserm U1061, France, Department of Dermatology and Allergy, Technische Universität München, Munich, Germany, ZAUM-Center for Allergy and Environment, Helmholtz Center Munich, Technische Universität München, Munich, Germany, Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France, AQuAS, Barcelna, Spain, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, Brazil, Social workers oordinator, Sorrento, Italy, Federal University of the State of Rio de Janeiro, School of Medicine and Surgery, Rio de Janeiro, Brazil, Allergology and Immunology Discipline, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania, Department of Medicine, Division of Clinical Immunology and Allergy, McMaster University, Hamilton, ON, Canada, Laboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes, Université Versailles Saint-Quentin, Université Paris Saclay, France, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Rangueil-Larrey Hospital, Respiratory Diseases Department, Toulouse, France, University Clinic of Pulmology and Allergy, Medical Faculty Skopje, North Macedonia, Service de Pneumo-Allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria, Clinic of infectious, chest diseases, dermatology and allergology, Vilnius University, Vilnius, Lithuania, Allergy and Clinical Immunology National Heart and Lung Institute, Imperial College London, United Kingdom, Guy’s and st Thomas’ NHS Trust, Kings College London, United Kingdom, Pediatric Allergy and Immunology Unit, Children’s Hospital, Ain Shams University, Cairo, Egypt, Department of Computing Science, Umeå University, Sweden and Four Computing Oy, Finland, University of São Paulo Medical School, Sao Paulo, Brazil, Andalusian Agency for Healthcare Quality, Seville, Spain, Global Allergy and Asthma Platform GAAPP, Vienna, Austria, Division of Allergy, Department of Pediatric Medicine-The Bambino Gesù Children’s Research Hospital Holy see, Rome, Italy, Department of Otorhinolaryngology, Amsterdam, University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technologies and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, MEDIDA, Lda, Porto, Portugal, AllergistReims, France, Hospital general regional 1 'Dr Carlos Mc Gregor Sanchez Navarro' IMSS, Mexico City, Mexico, Regional hospital of ISSSTE, Puebla, Mexico, National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia, Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, Department of Pulmonary Diseases, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istambul, Turkey, Allergology unit, UHATEM 'NIPirogov', Sofia, Bulgaria, Medical University, Faculty of Public Health, Sofia, Bulgaria, Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru, Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, Netherlands, Allergy & Asthma Unit, Hospital San Bernardo Salta, Argentina, Allergy Clinic, Hospital Regional del ISSSTE ‘Lic. López Mateos’, Mexico City, Mexico, Centro Regional de Excelencia CONACYT y WAO en Alergia, Asma e Inmunologia, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico, Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia, Latvian Association of Allergists, Center of Tuberculosis and Lung Diseases, Riga, Latvia, Federal District Base Hospital Institute, Brasília, Brazil, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc – National eHealth Centre, Czech Republic, Immunology and Allergy Division, Clinical Hospital, University of Chile, Santiago, Chile, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Centich: centre d’expertise national des technologies de l’information et de la communication pour l’autonomie, Gérontopôle autonomie longévité des Pays de la Loire, Conseil régional des Pays de la Loire, Centre d’expertise Partenariat Européen d’Innovation pour un vieillissement actif et en bonne santé, Nantes, France, Autonomous University of Baja California, Ensenada, Baja California, Mexico, Department of Paediatrics and Child Health, University College Cork, Cork, Ireland, Hospital General Regional 1 'Dr. Carlos MacGregor Sánchez Navarro' IMSS, Mexico City, Mexico, Université Paris-Sud, Service de Pneumologie, Hôpital Bicêtre, Inserm UMR_S999, Le Kremlin Bicêtre, France, Dipartimento di medicina, chirurgia e odontoiatria, università di Salerno, Italy, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples, Italy, Libra Foundation, Buenos Aires, Argentina, Medical University of Gdańsk, Department of Allergology, Gdansk, Poland, Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Hallym University College of Medicine, Hallym University Sacred Heart HospitalGyeonggi-do, South Korea, Department of Clinical Immunology, Wrocław Medical University, Poland, Ukrainina Medical Stomatological Academy, Poltava, Ukraine, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Hacettepe University, School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Ankara, Turkey, Allergy Centre, Tampere University Hospital, Tampere, Finland, First Department of Family Medicine, Medical University of Lodz, Poland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Germany, Department of Medicine, McMaster University, HealthSciences Centre 3V47, West, Hamilton, ON, Canada, National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of Molecular immunology, Moscow, Russian Federation, GARD Chairman, Geneva, Switzerland, Allergy & Asthma Center Westend, Berlin, Germany, Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, Lodz, Poland, Children’s Hospital and University of Helsinki, Finland, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Presidente CMMC, Milano, Italy, Head of the Allergy Department of Pedro de Elizalde Children’s Hospital, Buenos Aires, Argentina, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Federal University of Bahia, Brazil, Sifmed, Milano, Italy, State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, Departments of Internal Medicine and Pediatrics (Divisions of Allergy and Immunology), University of Tennessee College of Medicine, Germantown, TN, United States, Scottish Centre for Respiratory Research, Cardiovascular & Diabetes Medicine, Medical Research Institute, Ninewells Hospital, University of Dundee, United Kingdom, Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, Oslo, Norway, Department of Pulmonary Medicine, CHU Sart-Tilman, and GIGA I3 research group, Liege, Belgium, Department of Philosophical, Methodological and Instrumental Disciplines, CUCS, University of Guadalajara, Guadalajara, Mexico, Department of Pulmonary Medicine, Rashid Hospital, Dubai, United Arab Emirates, Biomax Informatics AG, Munich, Germany, Director Gerneral for Health and Social Care, Scottish Government, Edinburgh, United Kingdom, Department of Respiratory Medicine, University of Bratislava, Bratislava, Slovakia, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Portugal, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, Medical center Iskar Ltd Sofia, Bulgaria, Department of Medicine (RCSI), Bon Secours Hospital, Glasnevin, Dublin, Ireland, Kronikgune, International Centre of Excellence in Chronicity Research Barakaldo, Bizkaia, Spain, Division of Clinical Immunology and Allergy, Laboratory of Behavioral Immunology Research, The University of Mississippi Medical Center, Jackson, MS, United States, Tobacco Control Research Centre, Iranian Anti Tobacco Association, Tehran, Iran, Argentine Association of Allergy and Clinical Immunology, Buenos Aires, Argentina, University of Southeast Bahia, Brazil, Allergie-Centrum-Charité at the Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Germany, Maputo Central Hospital--Department of Paediatrics, Mozambique, Veracruz, Mexico, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Asthma Medical Group and Research Center, San Diego, CA, United States, Department of Physiology, CHRU, University Montpellier, Vice President for Research, PhyMedExp, INSERM U1046, CNRS UMR 9214, France, Croatian Pulmonary Society, Croatia, National Institute of Pneumology M Nasta, Bucharest, Romania, Clinic for Pulmonary Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Serbian Association for Asthma and COPD, Belgrade, Serbia, Regione Piemonte, Torino, Italy, Col Jardines de Sta Monica, Tlalnepantla, Mexico, National Center for Research in Chronic Respiratory Diseases, Tishreen University School of Medicine, Latakia, Syrian Arab Republic, Department of Public health and health products, Paris Descartes University-Sorbonne Paris Cité, EA 4064 and Paris Municipal Department of social action, childhood, and health, Paris, France, Paris municipal Department of social action, childhood, and health, Paris, France, Lead Respiratory Physician Mater Dei Hospital Malta, Academic Head of Dept and Professor of Medicine University of Malta, Deputy Dean Faculty of Medicine and Surgery University of Medicine, La Valette, Malta, Instituto de Prevision Social IPS HC, Socia de la SPAAI, Tesorera de la SLAAI, Asuncion, Paraguay, Universidade de São Paulo, São Paulo, Brazil, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Germany and CRI-Clinical Research International-Ltd, Hamburg, Germany, General Pathology Institute, Faculty of Medicine, University of Coimbra, Portugal, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain, Danish Commitee for Health Education, Copenhagen East, Denmark, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland and Honorary Research Fellow, OPC, Cambridge, United Kingdom, General Manager of COFASER-Pharmacy Services Consortium, Salerno, Italy, Scientific Centre of Children’s Health under the MoH, Moscow, Russian National Research Medical University named Pirogov, Moscow, Russian Federation, Dept of Otorhinolaryngology, Medical University of Vienna, AKH, Vienna, Austria, Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary, Die Hautambulanz and Rothhaar study center, Berlin, Germany, Neumología y Alergología Infantil, Hospital La Fe, Valencia, Spain, Center for Health Technology and Services Research-CINTESIS and Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal, Caisse d’assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France, Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy, ENT Department, University Hospital of Kinshasa, Kinshasa, Congo, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia, Medical center 'Research expert', Varna, Bulgaria, National Hospital Organization, Tokyo National Hospital, Tokyo, Japan, Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Dept of Otolaryngology, Nippon Medical School, Tokyo, Japan, Jalisco, Guadalarara, Mexico, Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso, Dept of Comparative Medicine, Messerli Research Institute of the University of Veterinary Medicine and Medical University, Vienna, Austria, Department of Immunology and Allergology, Faculty of Medicine and Faculty Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P&A Kyriakou,' University of Athens, Athens, Greece, Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea, Respiratory Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy, Allergy and Respiratory Diseases, Ospedale Policlino San Martino-University of Genoa, Italy, Farmacias Holon, Lisbon, Portugal, Department of Pediatrics, Nippon Medical School, Tokyo, Japan, University of Southern Denmark, Kolding, Denmark, Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Portugal, Sociologist, municipality area n33, Sorrento, Italy, Centre for empowering people and communites, Dublin, United Kingdom, Société de Pneumologie de Langue Française, Espace francophone de Pneumologie, Paris, France, Département de pédiatrie, CHU de Grenoble, Grenoble, France, Medical School, University of Cyprus, Nicosia, Cyprus, Children’s Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia, Karl Landsteiner Institute for Clinical and Experimental Pneumology, Hietzing Hospital, Vienna, Austria, University Hospital ‘Sv. Ivan Rilski’', Sofia, Bulgaria, Allergy Diagnostic and Clinical Research Unit, University of Cape Town Lung Institute, Cape Town, South Africa, IML, Milano, Italy, Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, Observational and Pragmatic Research Institute, Singapore, Singapore, Department of Otorhinolaryngology University of Crete School of Medicine, Heraklion, Greece, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Cancun, Quintana Roo, Mexico, LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany, Department of Medicine, Christian Albrechts University, Airway Research Center North, Member of the German Center for Lung Research (DZL), Kiel, Germany, Department of Nephrology and Endocrinology, Karolinska University Hospital, Stockholm, Sweden, Farmácia São Paio, Vila Nova de Gaia, Porto, Portugal, St Vincent’s Hospital and University of Sydney, Sydney, NSW, Australia, Puebla, Mexico, Serviço de Pneumologia-Hosp das Clinicas UFPE-EBSERH, Recife, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil, Centre of Pneumology, Coimbra University Hospital, Portugal, Polibienestar Research Institute, University of Valencia, Valencia, Spain, Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico City, Mexico, Getafe University Hospital Department of Geriatrics, Madrid, Spain, Association Asthme et Allergie, Paris, France, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, Primary Care Respiratory Research Unit Institutode Investigación Sanitaria de Palma IdisPa, Palma de Mallorca, Spain, Allergy Unit, Presidio Columbus, Rome, Catholic University of Sacred Heart, Rome and IRCCS Oasi Maria SS, Troina, Italy, Medical University of Graz, Department of Internal Medicine, Graz, Austria, Serviço de Imunoalergologia Hospital da Luz Lisboa, Portugal, Hospital de Clinicas, University of Parana, Brazil, Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, The University of Edinburgh, Edinburgh, United Kingdom, Showa University School of Medicine, Tokyo, Japan, Association of Finnish Pharmacies, Finland, Allergy and Clinical Immunology Department, Centro Médico-Docente la, Trinidad and Clínica El Avila, Caracas, Venezuela, Faculty of Medicine, Autnonous University of Madrid, Spain, The Royal National TNE Hospital, University College London, United Kingdom, DIBIMIS, University of Palermo, Italy, Asthma Reference Center, Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria-Esperito Santo, Brazil, THe Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, INSERM, Université Grenoble Alpes, IAB, U 1209, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Université Joseph Fourier, Grenoble, France, Sociedad Paraguaya de Alergia Asma e Inmunologı´a, Paraguay, Division of Allergy, Clinical Immunology and Rheumatology, Department of Pediatrics, Federal University of São Paulo, São Paulo, Brazil, European Health Futures Forum (EHFF), Dromahair, Ireland, ENT, Aachen, Germany, Kyrgyzstan National Centre of Cardiology and Internal medicine, Euro-Asian respiratory Society, Bishkek, Kyrgyzstan, University Hospital Olomouc, Czech Republic, Department of Paediatric and Adolescent medicine, University Hospital of North Norway, Tromsø, Paediatric Research Group, Deptarment of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway, Presidente, IML (Lombardy Medical Initiative), Bergamo, Italy, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Public Health Institute of Vilnius University, Vilnius, Lithuania, Universi-dade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, The Hospital for Sick Children, Dalla Lana School of Public Health, University of Toronto, Canada, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal, Depart-ment of ENT, Medical University of Graz, Austria, Campania Region, Division on Pharmacy and devices policy, Naples, Italy, Department of Respiratory Medicine, Hvidovre Hospital & University of Copenhagen, Denmark, Universidade Federal dos Pampas, Uruguaiana, Brazil, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain, Vilnius University Institute of Clinical Medicine, Clinic of Children’s Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, Department of Lung Diseases and Clinical Immunology Allergology, University of Turku and Terveystalo allergy clinic, Turku, Finland, PELyon, HESPER 7425, Health Services and Performance Resarch-Université Claude Bernard Lyon, France, Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet and University Hospital, Stockholm, Sweden, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Pulmonary Unit, Department of Medical Specialties, Arcispedale SMaria Nuova/IRCCS, AUSL di Reggio Emilia, Italy, FILHA, Finnish Lung Association, Helsinki, Finland, Pulmonary Environmental Epidemiology Unit, CNR Institute of Clinical Physiology, Pisa, Italy, CNR Institute of Biomedicine and Molecular Immunology 'A Monroy', Palermo, Italy, Medical University, Plovdiv, Bulgaria, Department of Otorhinolaryngology, Plovdiv, Bulgaria, Sotiria Hospital, Athens, Greece, Dept of Otorhinolaryngology, Universitätsklinikum Düsseldorf, Germany, Asthma UK, Mansell street, London, United Kingdom, Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Bradford Institute for Health Research, Bradford Royal Infirmary, Bradford, United Kingdom, Allergologyst-Medical College of Medical Faculty, Thracian University, Stara Zagora, Bulgaria, Department of Research, Olmsted Medical Center, Rochester, MN, United States, Cyprus International Institute for Environmental & Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus, Department of Pediatrics, Hospital 'Archbishop Makarios III', Nicosia, Cyprus, Celal Bayar University Department of Pulmonology, Manisa, Turkey, The Allergy and Asthma Institute, Pakistan, Department of Paediatrics and Child Health, Red Cross Children’s Hospital, and MRC Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital and Beijing Institute of Otolaryngology, Beijing, China, University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, and Akershus University Hospital, Department of Otorhinolaryngology, Akershus, Norway
- Abstract
mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an overview of the methods used in MASK and the key results obtained to date. These include a novel phenotypic characterization of the patients, confirmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary. © 2018 The Author(s).
- Published
- 2018
8. Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study.
- Author
-
Nakayasu H, Karayama M, Enomoto N, Inoue Y, Yasui H, Suzuki Y, Hozumi H, Furuhashi K, Kono M, Toyoshima M, Imokawa S, Fujii M, Akamatsu T, Koshimizu N, Yokomura K, Matsuda H, Kaida Y, Nakamura Y, Shirai M, Masuda M, Fujisawa T, Inui N, Sugiura H, Sumikawa H, Kitani M, Tabata K, Ogawa N, and Suda T
- Abstract
Background: Progressive pulmonary fibrosis (PPF) is a critical concern in interstitial lung disease (ILD) management. The HAL score, which incorporates honeycombing (H), age >75 years (A), and serum lactate dehydrogenase >222 U/L (L), can predict acute exacerbations in patients with idiopathic interstitial pneumonia (IIP). This study aims to evaluate the predictive utility of the HAL score for PPF development., Methods: This study was a post-hoc analysis of a multicenter prospective cohort study involving patients with IIP. PPF was diagnosed if at least two of the following three criteria were met: worsening respiratory symptoms, radiological progression, and physiological progression., Results: Among the 144 patients, 29 (22.3%) developed PPF during the observation period. Among the three criteria for PPF, a higher HAL score significantly correlated with worsening respiratory symptoms (p = 0.001) and radiological progression (p = 0.022), but not with physiological progression (p = 0.717). Therefore, a higher HAL score significantly correlated with an increased PPF risk (12.5% for a score of 0, 25.9% for a score of 1, and 33.3% for a score of ≥2; p = 0.032). The HAL score also correlated with overall survival (p < 0.001). For the 92 patients (70.8%) with non-idiopathic pulmonary fibrosis (IPF), the HAL score was significantly associated with PPF development (p = 0.021), while not for the 38 patients (29.2%) with IPF (p = 0.872)., Conclusion: In patients with non-IPF, the HAL score correlated with PPF development and could be useful to monitor those patients and to avoid missed treatment opportunities., Competing Interests: Conflict of interest The authors have no conflict of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Spontaneously regressing pulmonary tuberculosis detected by computed tomography in a patient with positive interferon-gamma release assay.
- Author
-
Kimura Y, Arai H, Tome R, Kaburaki K, and Sasada S
- Abstract
We present a case of pulmonary tuberculosis with a positive interferon-gamma release assay showing spontaneous regression followed by progression of radiological findings. Physicians should be aware that tuberculosis lesions can temporarily regress and careful follow up should be done if there are suspicious radiological findings., Competing Interests: None declared., (© 2024 The Author(s). Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)
- Published
- 2024
- Full Text
- View/download PDF
10. Association between preoperative antifungal therapy and postoperative complications in patients with pulmonary aspergilloma: A national database study in Japan.
- Author
-
Takeda K, Yokoyama A, Fukami T, Kimura Y, Suzukawa M, Jo T, Suzuki J, Sasaki Y, Mitani A, Tanaka G, Fujita A, Matsui H, Fushimi K, Nagase T, and Yasunaga H
- Subjects
- Humans, Japan epidemiology, Male, Female, Retrospective Studies, Aged, Middle Aged, Databases, Factual, Length of Stay, Adult, Pneumonectomy adverse effects, Antifungal Agents therapeutic use, Postoperative Complications microbiology, Postoperative Complications epidemiology, Postoperative Complications drug therapy, Pulmonary Aspergillosis surgery, Pulmonary Aspergillosis drug therapy, Preoperative Care
- Abstract
Postoperative complications of pulmonary resection in patients with pulmonary aspergilloma are common. Preoperative antifungal therapy is a perioperative management strategy to reduce postoperative complications; however, the benefit of the treatment remains controversial. A retrospective cohort study was conducted using data from the Diagnosis Procedure Combination database (July 2010-March 2021), a national inpatient database in Japan. Patients with pulmonary aspergilloma with or without chronic necrotizing pulmonary aspergillosis who underwent pulmonary resection were identified and divided into two groups based on whether they received preoperative antifungal therapy. Propensity-score overlap weighting was performed to compare the occurrence of composite postoperative complications and postoperative length of hospital stay between the two groups. We identified 98 patients with pulmonary aspergilloma who received preoperative antifungal therapy and 399 patients who did not. After propensity-score overlap weighting, the preoperative antifungal therapy group had a significantly lower proportion of composite postoperative complications than the non-preoperative antifungal therapy group (6.8% vs. 14.2%, P = .038). There was no significant difference in postoperative length of stay between the groups with and without preoperative antifungal therapy (median 14.6 vs. 15.8 days, P = .41). Preoperative antifungal therapy was associated with a reduction in postoperative complications in patients with pulmonary aspergilloma. Preoperative treatment with antifungals may be beneficial in reducing the risk of postoperative complications in patients with pulmonary aspergilloma undergoing pulmonary resection., (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.)
- Published
- 2024
- Full Text
- View/download PDF
11. Helicobacter pylori Seroprevalence in Rheumatoid Arthritis Patients with Interstitial Lung Disease.
- Author
-
Oka S, Higuchi T, Furukawa H, Shimada K, Okamoto A, Fujimori M, Hashimoto A, Komiya A, Saisho K, Yoshikawa N, Katayama M, Matsui T, Fukui N, Migita K, and Tohma S
- Abstract
Background: Rheumatoid arthritis (RA) is complicated with interstitial lung disease (ILD). Gastroesophageal reflux disease is prevented by Helicobacter pylori infection and is a predisposing factor for idiopathic pulmonary fibrosis. However, the prevalence of H. pylori infection in RA patients with ILD has not been sufficiently investigated., Objective: In this study, we analyzed anti- H. pylori antibodies in RA patients with ILD., Design: Case-control observational study., Methods: Anti- H. pylori antibodies were analyzed in the sera of RA patients using a commercially available enzyme-linked immunosorbent assay kit., Results: The positivity of anti- H. pylori antibodies in RA with ILD ( n = 30 [18.0%], P = .0227), usual interstitial pneumonia ( n = 10 [14.3%], P = .0212), and airway disease ( n = 30 [18.0%], P = .0227) was significantly lower than that of RA without chronic lung disease ( n = 78 [27.5%]). The positivity of anti- H. pylori antibodies was also lower in RA with chronic lung disease ( n = 68 [18.2%], P = .0059). Multiple logistic regression analyses showed that the presence of anti- H. pylori antibodies was independently and protectively associated with chronic lung disease in RA., Conclusion: The seroprevalence of H. pylori was lower in RA with ILD. H. pylori infection prevented ILD in patients with RA by protecting them from gastroesophageal reflux disease., (© The Author(s) 2024.)
- Published
- 2024
- Full Text
- View/download PDF
12. Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial.
- Author
-
Masaki K, Suzukawa M, Sasano H, Harada N, Miyazaki Y, Katsura H, Tagaya E, Terada J, Hojo M, Sugimoto N, Nagase H, Kono Y, Hiranuma H, Gon Y, Takemura R, Irie M, Nakamura R, Kabata H, Miyata J, and Fukunaga K
- Abstract
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe asthma., Methods: This prospective, interventional, single-arm clinical trial was conducted across ten facilities in Japan between September 2020 and July 2022. Adult patients with severe eosinophilic asthma (peripheral blood eosinophil count ≥150 cells/μl) were enrolled and treated with benralizumab. The primary endpoint was the change in ACQ-5 score from baseline to week 24., Results: Of 103 patients, 98 (mean age: 62.1 years, women: 55.1 %, regular oral corticosteroids [OCS] treatment: 20.4 %) were included in the analysis. From baseline to week 24, benralizumab significantly improved ACQ-5 (-0.67, 95 % CI: -0.94 to -0.39) and AQLQ (0.71, 95 % CI: 0.46 to 0.96) scores with an increase in FEV1 (87 ml, 95 % CI: 15-159 ml). The maintenance OCS dose and the percentage of OCS users decreased from 13.9 mg/day to 6.0 mg/day and from 20.4 % to 9.2 %, respectively. Multivariable analysis identified baseline blood eosinophil count (≥400 cells/μl) and fractional exhaled nitric oxide (≥22 ppb) as independent predictors of therapeutic response to benralizumab. Benralizumab treatment was discontinued due to nonserious adverse events and patient choice in four and three patients, respectively., Conclusions: In a real-world setting in Japan, patients with severe eosinophilic asthma treated with benralizumab demonstrated substantial improvements in asthma control, quality of life, and respiratory function with reduced OCS usage., Trial Registration: Japan Registry of Clinical Trials (jRCTs031190237)., Competing Interests: Conflict of interest KM, MS, NH, YM, ET, MH, HN, HKab, JM, KF received honoraria for lectures from AstraZeneca. HN has received fee for advisory board from AstraZeneca. The rest of the authors have no conflict of interest., (Copyright © 2024 Japanese Society of Allergology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Infliximab rather than tocilizumab for HLA-B52-positive Takayasu arteritis?
- Author
-
Takamasu E, Yokogawa N, Furukawa H, Oka S, and Shimada K
- Abstract
Competing Interests: Compliance with ethical standards. Disclosures: None. Ethical approval: The institutional ethics committee of Tokyo Metropolitan Tama Medical Center approved this study (No. 5–84), and the requirement for case consent was substituted by proving opportunities to opt out because of its retrospective design.
- Published
- 2024
- Full Text
- View/download PDF
14. Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis.
- Author
-
Sengupta A, Ray A, Upadhyay AD, Izumikawa K, Tashiro M, Kimura Y, Bongomin F, Su X, Maitre T, Cadranel J, de Oliveira VF, Iqbal N, Irfan M, Uzunhan Y, Aguilar-Company J, Munteanu O, Beardsley J, Furuuchi K, Takazono T, Ito A, Kosmidis C, and Denning DW
- Abstract
Background: Despite antifungal treatment, chronic pulmonary aspergillosis (CPA) is associated with substantial morbidity and mortality. We conducted a systematic review and meta-analysis to evaluate rates of mortality and its predictors in CPA., Methods: A systematic literature search was conducted across MEDLINE (PubMed), Scopus, Embase, and Web of Science to identify studies in English, reporting mortality in CPA, from database inception to Aug 15, 2023. We included clinical studies, observational studies, controlled trials, and abstracts. Case reports, animal studies, letters, news, and literature reviews were excluded. Authors of studies published since 2016 were also contacted to obtain anonymised individual patient data (IPD); for other studies, summary estimates were extracted. Subgroup analysis was done for differences in overall 1-year and 5-year mortality, data source, study design, risk of bias, country, Human Development Index, age groups, and the underlying lung disease. We used random-effects meta-analyses to estimate pooled mortality rates. Subgroup analyses and meta-regression were done to explore sources of heterogeneity. One-stage meta-analysis with a stratified Cox proportional hazards model was used to estimate the univariable and hazards for mortality, adjusting for age, sex, type of CPA, treatment, and underlying pulmonary comorbidities. This study was registered with PROSPERO (CRD42023453447)., Findings: We included 79 studies involving 8778 patients in the overall pooled analysis and 15 studies involving 1859 patients in the IPD meta-analysis. Pooled mortality (from 70 studies) was estimated at 27% overall (95% CI 22-32; I
2 =95·4%), 15% at 1 year (11-19; I2 =91·6%), and 32% at 5 years (25-39; I2 =94·3%). Overall mortality in patients with CPA with pulmonary tuberculosis as the predominant predisposing condition was 25% (16-35; I2 =87·5%; 20 studies) and with chronic obstructive pulmonary disease was 35% (22-49; I2 =89·7%; 14 studies). Mortality in cohorts of patients who underwent surgical resection was low at 3% (2-4). In the multivariable analysis, among predisposing respiratory conditions, pulmonary tuberculosis history had the lowest mortality hazard (relative to an absence of the disease at baseline), whereas worse outcomes were seen with underlying malignancy; subacute invasive pulmonary aspergillosis and chronic cavitary pulmonary aspergillosis subtypes of CPA were also significantly associated with increased mortality relative to simple aspergilloma on multivariable analysis. Mortality hazard increased by 25% with each decade of age (adjusted hazard ratio 1·25 [95% CI 1·14-1·36], p<0·0001)., Interpretation: CPA is associated with substantial mortality. Advancing age, CPA subtype, and underlying comorbidities are important predictors of mortality. Future studies should focus on identifying appropriate treatment strategies tailored to different risk groups., Funding: None., Competing Interests: Declaration of interests AR has received a grant from Jolly Healthcare. KI has received payments from Pfizer Japan. MT has received grants from the Japan Society for the Promotion of Science and The Rotary Foundation; consulting fees from Asahi Kasei Pharma; and honoraria from Sumitomo Pharma, Kyorin Holdings, Astellas Pharma, Ono Pharmaceutical, Fujifilm Toyama Chemical, Chugai Pharmaceutical, Asahi Kasei Pharma, Janssen Pharmaceutical, and Shionogi Healthcare. TT has received consulting fees or honoraria for speaking from Asahikasei, Insmed, and Shionogi. DWD and family hold founder shares in F2G, a University of Manchester spin-out antifungal discovery company; and hold share options in TFF Pharmaceuticals. DWD acts or has recently acted as a consultant to Pulmocide, Biosergen, TFF Pharmaceuticals, Rostra Therapeutics, Pfizer, Mundipharma, Lifemine, and Cipla; chairs a data review committee for Pulmocide and Biosergen; has (in the past 3 years) been paid for talks on behalf of Hikma, Gilead, Avni, Pfizer, and Knight; and has contributed to multiple guidelines related to aspergillosis and fungal diagnostics. All other authors declare no competing interests., (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
15. Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol.
- Author
-
Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, Saegusa J, Sato S, Matsubara T, Yamaoka K, Amano K, Miyamoto T, Mori Y, and Kaneko Y
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Herpesvirus 3, Human immunology, Multicenter Studies as Topic, Pyrimidines therapeutic use, Pyrimidines administration & dosage, Randomized Controlled Trials as Topic, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Herpes Zoster prevention & control, Herpes Zoster Vaccine administration & dosage, Herpes Zoster Vaccine immunology, Janus Kinase Inhibitors therapeutic use, Janus Kinase Inhibitors administration & dosage, Piperidines therapeutic use, Piperidines administration & dosage
- Abstract
Introduction: Janus kinase (JAK) inhibitors are an important therapeutic option in the treatment of rheumatoid arthritis, but increase the risk of developing herpes zoster. Although a dry recombinant zoster vaccine (RZV) that can be used under immunosuppressive conditions has recently been developed, its optimal use and appropriate timing in patients scheduled to start JAK inhibitors is still unclear. The present study is designed to clarify the appropriate timing of JAK inhibitor initiation to measure varicella zoster virus (VZV)-specific IgG titers and VZV-specific T cell response in patients with rheumatoid arthritis who start tofacitinib at the first RZV vaccination or at the second one., Methods and Analysis: STOP HZ (Effectiveness and S afe T y O f P rophylactic Recombinant H erpes Z oster Virus Vaccination for Rheumatoid Arthritis Patients with Tofacitinib Treatment) study is a multicentre, open-label, randomised, comparative study in patients with rheumatoid arthritis who are scheduled to start tofacitinib. This study enrols 60 study subjects in 12 sites. Enrolled subjects receive RZV two times on day 1 and week 8 and initiate tofacitinib 5 mg two times a day at the time of their first RZV (day 1, group A) or second RZV (week 8, group B) based on randomisation. The random assignment is performed centrally in a 1:1 ratio. Patients in Group B continue the same treatment until the start of tofacitinib treatment. Primary endpoint is VZV-specific IgG antibody titers at week 12 compared with those at baseline in each group. Secondary endpoints include comparison of VZV-specific IgG antibody between the groups, changes in disease activity of rheumatoid arthritis, VZV-specific T cell response and adverse events., Ethics and Dissemination: The study has been approved by the Certified Review Board of Keio (No. 2022008), and conforms to the Declaration of Helsinki and good clinical practice guidelines. Written informed consent is obtained from participants prior to enrolment. The results of this study are planned to be submitted for publishment in relevant peer-review journals., Trial Registration Number: jRCTs031230329., Competing Interests: Competing interests: STa has received honoraria from Abbvie, Astellas, Eisai, Eli Lilly and Pfizer. KO has received honoraria and research support from Eisai, Gilead and AstraZeneca. KM has received honoraria and research support from AbbVie, Eli Lilly and Company, Eisai and Ono Pharmaceutical Co. Ltd. AI received research grant and speaker fees from AbbVie, Asahikasei, AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, Ono, Pfizer, Tanabe and Taisho pharmaceutical. TMatsui has received honoraria and research support from Pfizer, Chugai Pharmaceutical Co. Ltd and AsahiKASEI Co. Ltd. STo has received honoraria and research support from Pfizer Japan, Abbvie Japan Co. Ltd, Chugai pharmaceutical Co. Ltd, AsahiKASEI Co. Ltd, Mitsubishi-Tanabe Pharm Co, Eisai Co. Ltd. Janssen pharmaceutical K.K. SS has received honoraria, research support from Eisai Pharma and received honoraria from Abbvie, GlaxoSmithKline, Eli lilly, Pfizer, Astellas Pharma. TMatsub has received research support and/or speaker honoraria from Astellas Pharma, Bristol-Myers Squibb., AbbVie GK, Eli Lilly Japan K.K., Pfizer Japan, Gilead Sciences K.K. and AYUMI Pharmaceutical Corporation. KY has received honoraria, consultant fees and research support from Pfizer, Abbvie, GlaxoSmithkline, Eli lilly, Astellas Pharma, Gilead G.K., Eisai Pharma. KA has received honoraria from Pfizer Japan and GlaxoSmithKline. YK has received research grants and speaking fees from AbbVie, Astellas, Eisai, Eli Lilly, Pfizer and Gilead Sciences. JS, TMi and YM have no conflict of interest., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
16. Serum Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibody Levels Are Involved in Rheumatoid Arthritis Complicated with Interstitial Lung Disease.
- Author
-
Oka S, Higuchi T, Furukawa H, Shimada K, Okamoto A, Fujimori M, Hashimoto A, Komiya A, Saisho K, Yoshikawa N, Katayama M, Matsui T, Fukui N, Migita K, and Tohma S
- Abstract
Objectives: A common complication in patients with rheumatoid arthritis (RA) is interstitial lung disease (ILD). Antibodies (Abs) to anti-aminoacyl-transfer ribonucleic acid synthetase (ARS) are linked to ILD in patients with idiopathic inflammatory myopathies (IIM). There have been limited studies of anti-ARS Abs in RA. In this study, we examined anti-ARS Abs in ILD in patients with RA. Methods: Anti-ARS Abs in serum from patients with RA were measured. Results: There were higher anti-ARS Ab levels in RA patients with ILD (mean ± SDM, 16.3 ± 32.3 vs. 7.4 ± 7.0 (Index), p = 5.58 × 10
-12 ), usual interstitial pneumonia (14.4 ± 24.4 vs. 7.4 ± 7.0 [Index], p = 3.14 × 10-12 ), and nonspecific interstitial pneumonia (17.9 ± 37.7 vs. 7.4 ± 7.0 (Index), p = 5.07 × 10-5 ) compared with patients without chronic lung disease. The area under the curve (AUC) of the receiver operating characteristic curve for anti-ARS Ab was too low to allow for discrimination among RA patients with/without chronic lung disease (0.608, 95% confidence interval (CI) 0.560-0.655, p = 8.69 × 10-6 ). Multiple logistic regression analyses of age, smoking status, anti-ARS Abs, as well as Steinbrocker stage generated an ARS-index with a high AUC value (0.707, 95%CI 0.662-0.752, p = 2.20 × 10-19 ). Conclusions: Anti-ARS Abs are related to ILD pathogenesis in RA and may be a biomarker for ILD.- Published
- 2024
- Full Text
- View/download PDF
17. New diagnostic criteria and current issues for pulmonary hypertension.
- Author
-
Kusaka K, Takeda K, Kawashima M, and Morio Y
- Subjects
- Humans, Pulmonary Wedge Pressure physiology, Hemodynamics, Societies, Medical, Severity of Illness Index, Pulmonary Artery physiopathology, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary physiopathology, Hypertension, Pulmonary etiology, Vascular Resistance
- Abstract
In 2022, the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) proposed new diagnostic criteria for pulmonary hypertension (PH). These criteria include significant changes to the definitions of pulmonary hemodynamic indices. Specifically, the threshold for mean pulmonary artery pressure (mPAP) has been lowered from ≥25 mmHg to >20 mmHg, and the threshold for pulmonary vascular resistance (PVR) has been adjusted from ≥3 Wood units (WU) to >2 WU. Additionally, the diagnostic criterion for exercise-induced PH has been reintroduced. To differentiate between non-severe and severe PH associated with lung disease, a differential threshold of 5 WU for PVR has been proposed. However, the threshold for mean pulmonary artery wedge pressure (PAWP) remains unchanged. While these new criteria could provide a more refined approach to clinical practice, they may also raise clinical concerns and questions regarding the diagnosis and management of PH., Competing Interests: Declaration of Competing interest The authors have no conflicts of interest., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Clinical research using real-world data: A narrative review.
- Author
-
Kimura Y, Jo T, Matsui H, and Yasunaga H
- Subjects
- Humans, Randomized Controlled Trials as Topic, Biomedical Research, Japan, Databases, Factual
- Abstract
Randomized controlled trials (RCTs) and studies using real-world data (RWD) each have their strengths and weaknesses, and can effectively complement each other. When RCTs are not feasible, RWD studies offer a valuable alternative. In this narrative review, we examine several types of RWD studies, focusing on studies utilizing administrative claims databases. These include the Diagnosis Procedure Combination databases, commercially available health checkups and healthcare claims databases (such as the JDMC and DeSC databases), and the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Given that these claims databases cover different populations, patient settings, variables, and levels of accessibility, it is crucial for researchers to select the most appropriate data source to effectively address their research questions. Additionally, it is desirable for readers of studies using these databases to be aware of their characteristics in order to fully understand the context and limitations of the research findings., (Copyright © 2024 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
19. Urgent Contrast-Enhanced Computed Tomography before Early Colonoscopy in the Management of Colonic Diverticular Bleeding: A Multicenter Randomized Controlled Trial.
- Author
-
Hirai Y, Uraoka T, Wada M, Mori H, Fujimoto A, Sakakibara Y, Toyokawa T, Kagaya T, Sasaki Y, Mannami T, Kuwai T, Watanabe N, Hamada H, Esaka N, Kimura T, Fujii H, Hosoda Y, Shimada M, Miyabayashi H, Somada S, Mabe K, Inoue S, Saito H, Furuya K, Kawamura N, Kudo T, Hori K, Sakamoto N, Kato M, Higuchi N, and Harada N
- Abstract
Introduction: Contrast-enhanced computed tomography (CE-CT) has been gaining attention as an initial investigation in the management of colonic diverticular bleeding (CDB), yet the role of CE-CT other than its diagnostic yield has not been adequately clarified. We aimed to determine whether the use of urgent CE-CT improves identification of stigmata of recent hemorrhage (SRH) in subsequently performed early colonoscopy (≤24 h of arrival) or other clinical outcomes of CDB., Methods: We conducted a randomized, open-label, controlled trial at 23 institutions in Japan. Outpatients with suspected CDB were randomly assigned to undergo either urgent CE-CT followed by early colonoscopy (urgent-CE-CT + early-colonoscopy group) or early colonoscopy alone (early-colonoscopy group). The primary outcome was SRH identification. Secondary outcomes included successful endoscopic hemostasis, early (<30 days) and late (<1 year) rebleeding, length of hospital stay, and transfusion requirements., Results: In total, 240 patients, mostly in a hemodynamically stable condition, were randomized. A contrast extravasation on CE-CT was observed in 20 of 115 patients (17.4%) in the urgent-CE-CT + early-colonoscopy group. SRH was identified in 23 of 115 patients (20.0%) in the urgent-CE-CT + early-colonoscopy group and 21 of 118 patients (17.8%) in the early-colonoscopy group (difference, 2.2; 95% confidence interval [CI], -7.9 to 12.3; p = 0.739). Successful endoscopic hemostasis was achieved in 21 patients in each group (18.3% and 17.8%, respectively) (difference, 0.5; 95% CI, -9.4 to 10.4; p = 1.000). There were also no significant differences between groups in early and late rebleeding, length of hospital stay, and transfusion requirements., Conclusion: The use of urgent CE-CT before early colonoscopy did not improve SRH identification or other clinical outcomes in patients with suspected CDB in a hemodynamically stable condition. The routine use of urgent CE-CT as an initial investigation is not recommended in this population, also considering the low rate of extravasation-positive cases (UMIN registry number, UMIN000026865)., (© 2024 S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
20. Identification of exhaled volatile organic compounds that characterize asthma phenotypes: A J-VOCSA study.
- Author
-
Suzukawa M, Ohta K, Sugimoto M, Ohshima N, Kobayashi N, Tashimo H, Tanimoto Y, Itano J, Kimura G, Takata S, Nakano T, Yamashita T, Ikegame S, Hyodo K, Abe M, Chibana K, Kamide Y, Sasaki K, and Hashimoto H
- Subjects
- Humans, Male, Female, Middle Aged, Cross-Sectional Studies, Adult, Biomarkers, Gas Chromatography-Mass Spectrometry, Aged, Japan, Asthma diagnosis, Asthma metabolism, Volatile Organic Compounds analysis, Phenotype, Breath Tests methods, Exhalation
- Abstract
Background: Asthma is characterized by phenotypes of different clinical, demographic, and pathological characteristics. Identifying the profile of exhaled volatile organic compounds (VOCs) in asthma phenotypes may facilitate establishing biomarkers and understanding asthma background pathogenesis. This study aimed to identify exhaled VOCs that characterize severe asthma phenotypes among patients with asthma., Methods: This was a multicenter cross-sectional study of patients with severe asthma in Japan. Clinical data were obtained from medical records, and questionnaires were collected. Exhaled breath was sampled and subjected to thermal desorption gas chromatography-mass spectrometry (GC/MS)., Results: Using the decision tree established in the previous nationwide asthma cohort study, 245 patients with asthma were divided into five phenotypes and subjected to exhaled VOC analysis with 50 healthy controls (HCs). GC/MS detected 243 VOCs in exhaled breath samples, and 142 frequently detected VOCs (50% of all samples) were used for statistical analyses. Cluster analysis assigning the groups with similar VOC profile patterns showed the highest similarities between phenotypes 3 and 4 (early-onset asthma phenotypes), followed by the similarities between phenotypes 1 and 2 (late-onset asthma phenotypes). Comparisons between phenotypes 1-5 and HC revealed 19 VOCs, in which only methanesulfonic anhydride showed p < 0.05 adjusted by false discovery rate (FDR). Comparison of these phenotypes yielded several VOCs showing different trends (p < 0.05); however, no VOCs showed p < 0.05 adjusted by FDR., Conclusions: Exhaled VOC profiles may be useful for distinguishing asthma and asthma phenotypes; however, these findings need to be validated, and their pathological roles should be clarified., (Copyright © 2024 Japanese Society of Allergology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study.
- Author
-
Enomoto N, Nakai S, Yazawa S, Mochizuka Y, Fukada A, Tanaka Y, Naoi H, Inoue Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Furuhashi K, Toyoshima M, Kono M, Imokawa S, Fujii M, Akamatsu T, Koshimizu N, Yokomura K, Matsuda H, Kaida Y, Nakamura Y, Shirai M, Mori K, Masuda M, Fujisawa T, Inui N, Sugiura H, Sumikawa H, Kitani M, Tabata K, Ogawa N, and Suda T
- Subjects
- Humans, Female, Male, Prospective Studies, Aged, Middle Aged, Cohort Studies, Predictive Value of Tests, Idiopathic Pulmonary Fibrosis diagnosis, Idiopathic Pulmonary Fibrosis blood, Idiopathic Pulmonary Fibrosis immunology, Prognosis, Aged, 80 and over, Chemokine CXCL10 blood, Biomarkers blood
- Abstract
Background: Interstitial pneumonia with autoimmune features (IPAF), which does not meet any of the criteria for connective tissue diseases (CTD), has been attracting an attention in patients with idiopathic interstitial pneumonia (IIP). However, the biomarkers that reflect the clinical course of these patients have not been fully elucidated., Objective: To identify useful serum biomarkers reflecting CTD-related features and favorable prognoses in patients with IIP., Methods: This was a post hoc analysis of a prospective and multicenter cohort study between 2015 and 2020. Newly diagnosed patients with IIP were consecutively enrolled, and 74 autoimmune features and autoantibodies were comprehensively checked during IIP diagnosis. Serum levels of CXCL10, CXCL1, CCL2, BAFF, angiopoietin-2, and leptin were evaluated at the time of IIP diagnosis., Results: Two hundred twenty-two patients (159 men and 63 women) with IIP were enrolled. The median observation duration was 36 months. The median age was 71 years old, and median %forced vital capacity (FVC) was 84.1% at the time of IIP diagnosis. The proportion of patients who met the classification criteria for IPAF was 11.7%. In patients with high serum CXCL10, changes in both %FVC and %diffusion lung capacity for carbon monoxide at one year were significantly higher than those in patients with low CXCL10 (p = 0.014 and p = 0.009, respectively), whereas these changes were not significant for other chemokines and cytokines. High CXCL10 levels were associated with acute/subacute onset (p < 0.001) and the diagnosis of nonspecific interstitial pneumonia with organizing pneumonia overlap (p = 0.003). High CXCL10 levels were related to a higher classification of IPAF (relative risk for IPAF was 3.320, 95%CI: 1.571-7.019, p = 0.003) and lower classification of progressive pulmonary fibrosis (PPF; relative risk for PPF was 0.309, 95%CI: 0.100-0.953, p = 0.027) compared to those with low CXCL10. Finally, survival was higher in patients with IPF and high CXCL10 (p = 0.044), and high CXCL10 was a significant prognostic factor in multivariate Cox proportional hazards models (hazard ratio 0.368, p = 0.005)., Conclusions: High serum levels of CXCL10 are associated with CTD-related features, the favorable clinical course, and survival in patients with IIP, especially IPF., Clinical Trial Number: Not applicable., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
22. Cold temperatures during sample transportation may cause false-negative interferon-γ release assays used to diagnose TB infection.
- Author
-
Takeda K, Nagai H, Kawashima M, Kosai I, Shimozono M, Sato K, Motomura H, Nakano E, Watanabe M, Kato T, Shimada M, Narumoto O, Suzukawa M, Suzuki J, Yamane K, Sasaki Y, Morio Y, Tamura A, and Matsui H
- Subjects
- Humans, False Negative Reactions, Cold Temperature, Interferon-gamma Release Tests, Specimen Handling, Tuberculosis diagnosis
- Published
- 2024
- Full Text
- View/download PDF
23. Relationship between serum IgA levels and low percentage forced expiratory volume in the first second in asthma.
- Author
-
Imoto S, Suzukawa M, Takada K, Watanabe S, Isao A, Nagase T, Nagase H, and Ohta K
- Subjects
- Humans, Male, Female, Forced Expiratory Volume, Middle Aged, Adult, Chemokine CCL11 blood, Chemokine CCL4 blood, Aged, Asthma blood, Asthma immunology, Asthma physiopathology, Immunoglobulin A blood, Biomarkers blood
- Abstract
Objective: Immunoglobulin A (IgA) is suggested to have pathogenic effects in respiratory inflammatory diseases, including asthma. We aimed to analyze the relationship between serum IgA, and clinical indicators and biomarkers of asthma. Methods: This study was a post hoc analysis of the NHOM Asthma Study. In this study, serum IgA was measured using serum samples stored. We determined an association between the serum IgA level and clinical variables and biomarkers using multivariate linear regression and analyzed the differences in clinical indices between IgA high- and IgA low-asthma. Results: In this study, 572 patients with asthma were included in the final analysis. Lower percentage forced expiratory volume in the first second (%FEV
1 ), higher serum eotaxin levels, lower serum ST2 levels, and higher serum MIP-1β levels, were independently and significantly associated with higher serum IgA levels among asthma patients by multivariate linear regression analysis (%FEV1 , 95% confidence interval [CI], -8.18- -0.613, p < 0.05; eotaxin, 95% CI, 8.95-46.69, p < 0.001; ST2, 95% CI, -73.71- -7.37, p < 0.05; and MIP-1β, 95% CI, 1.47-18.71, p < 0.05). Furthermore, IgA high-asthma (serum IgA ≥ 238 mg/dL, n = 270) and IgA low-asthma (serum IgA < 238 mg/dL, n = 302) were compared separately. %FEV1 was significantly lower, the percentage of atopy was higher, and serum MIP-1β level was higher in IgA high-asthma. Conclusions: This study suggests that serum IgA may be involved in the worsening of asthma outcomes, as assessed by %FEV1 and enhanced inflammation via elevated serum MIP-1β.- Published
- 2024
- Full Text
- View/download PDF
24. Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air ® .
- Author
-
Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Czarlewski W, Ansotegui IJ, Bergmann KC, Braido F, Brussino L, Cecchi L, Loureiro CC, Cruz AA, Devillier P, Fiocchi A, Gemicioglu B, Haahtela T, Ivancevich JC, Klimek L, Kulus M, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Louis G, Louis R, Makris M, Morais-Almeida M, Niedoszytko M, Ohta K, Ollert M, Papadopoulos N, Patella V, Pétré B, Pfaar O, Puggioni F, Quirce S, Regateiro FS, Roche N, Rouadi PW, Samolinski B, Sastre J, Schleich F, Scichilone N, Taborda-Barata L, Toppila-Salmi S, Valiulis A, Vardaloglu Koyuncu I, Ventura MT, Yorgancioglu A, Fonseca JA, and Zuberbier T
- Abstract
Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK-air
® (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut-offs and responsiveness. Then, a multicentric, multinational, double-blind, placebo-controlled, randomised control trial (DB-PC-RCT) using an electronic VAS form was carried out. Finally, with the development of MASK-air® in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ-5D are included in the app. Additionally, two control-medication scores for allergic symptoms of asthma (e-DASTHMA) were validated for their criterion validity, cut-offs and responsiveness., (© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)- Published
- 2024
- Full Text
- View/download PDF
25. Mechanisms of resistance and correlation between pre-treatment co-alterations and p-prognosis to osimertinib in chemo-naïve advanced non-small cell lung cancer.
- Author
-
Tamiya A, Osuga M, Harada D, Isa SI, Taniguchi Y, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, and Koh Y
- Subjects
- Humans, Female, Male, Aged, Prospective Studies, Prognosis, Middle Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Adult, Biomarkers, Tumor genetics, ErbB Receptors genetics, Indoles, Pyrimidines, Acrylamides therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Aniline Compounds therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms mortality, Lung Neoplasms pathology, Drug Resistance, Neoplasm genetics, Mutation
- Abstract
Background: Several patients treated with osimertinib experience progressive disease. The aim was to clarify the mechanisms underlying resistance to osimertinib., Methods: ELUCIDATOR: A multi-centre, prospective, observational study involved chemotherapy-naive patients with advanced non-small cell lung cancer receiving osimertinib. Mutations in cancer-associated genes, detected via ultrasensitive next-generation sequencing of circulating tumour deoxyribonucleic acid samples, were collected at baseline and after progressive disease detection. These paired plasma samples were compared., Results: Of 188 patients enrolled (May 2019-January 2021), 178 (119 females [67 %]) median age 74 years, were included. Patients, n = 95 (53 %) had epidermal growth factor receptor exon 19 deletion mutations. Among 115 patients with progressive disease, circulating tumour deoxyribonucleic acid levels of 85 patients were analysed. MET amplification (n = 4), TP53 mutations (n = 4), PIK3CA mutations (n = 3), BRINP3 mutation (n = 2), BRAF mutation (n = 2), APC mutation (n = 1), RET mutation (n = 1) and epidermal growth factor receptor (EGFR) resistance mutation, and C797S (n = 1) were detected. Patients with baseline TP53 mutations, with MET or EGFR amplification had shorter progression-free (PFS) and overall survival. Patients with PIK3CA mutations tended to shorter PFS., Conclusion: MET amplification and PIK3CA mutation mechanisms underly resistance to osimertinib in patients. Patients with coexisting mutations or amplifications at baseline had shorter PFS and overall survival., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. ZFP36 family expression is suppressed by Th2 cells in asthma, leading to enhanced synthesis of inflammatory cytokines and cell surface molecules.
- Author
-
Uehara Y, Suzukawa M, Horie M, Igarashi S, Minegishi M, Takada K, Saito A, and Nagase H
- Subjects
- Humans, Inflammation immunology, Female, Male, Adult, Gene Expression Regulation, RNA, Messenger genetics, RNA, Messenger metabolism, Transcription Factors, Butyrate Response Factor 1, Asthma immunology, Asthma metabolism, Tristetraprolin metabolism, Tristetraprolin genetics, Cytokines metabolism, Th2 Cells immunology, Th2 Cells metabolism
- Abstract
Asthma is a chronic inflammatory airway disease, in which inflammatory cytokines play a pivotal role. The zinc finger binding protein 36 (ZFP36) family includes ZFP36, ZFP36L1, and ZFP36L2 and is among the RNA-binding proteins (RBPs) reported to cause inflammation. The present study aimed to clarify the roles of the ZFP36 family in asthma, particularly highlighting the relationship between the ZFP36 family and Th2 cells, which are key players in type 2 inflammation in asthma. Real-time PCR analysis revealed the preferential expression of ZFP36 family mRNAs in human white blood cells. Gene expression analysis using public datasets from the GEO database (https://www.ncbi.nlm.nih.gov/gds) showed significantly suppressed expression of ZFP36 family mRNAs in patients with asthma compared to that in healthy controls. Using multiple cytokine assays, Th2 cell transfection with ZFP36 family siRNAs enhanced the expression of inflammatory cytokines IL-8, IFN-γ, CCL3/MIP-1α, CCL4/MIP-1β, and TNF-α and cell surface molecules CCR4 (CD194) and PSGL-1 (CD162). Treatment with IL-2, 4, and 15 significantly suppressed, and corticosteroid significantly enhanced the expressions of ZFP36 family mRNAs by Th2 cells. In conclusion, the ZFP36 family expressed by Th2 cells was suppressed in patients with asthma, leading to the enhanced expression of cytokines and cell surface molecules. Suppressed ZFP36 expression in asthma may be involved in the enhancement of airway inflammation, and the ZFP36 family may be a therapeutic target for inflammatory diseases, including asthma., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Clinical analysis of progressive destroyed lung after lung cancer surgery.
- Author
-
Iida T, Sato M, and Fukami T
- Abstract
Background: "Progressive destroyed lung (PDL)" refers to a state in which the normal structure and function of the lung are permanently disrupted owing to repeated inflammation. After lung cancer surgery, the remaining lung tissue can experience progressive destruction; however, the exact cause remains unclear. In this study, we retrospectively analyzed cases in which the remaining lung deteriorated after lung cancer surgery and investigated the associated risk factors., Methods: A case-control study was conducted on 31 cases of PDL and 247 cases of non-PDL among 1,234 patients who underwent surgery for primary lung cancer from 2006 to 2021. The following factors were analyzed: age, sex, medical history, smoking status, surgical procedure, lung cancer histology, surgical approach, postoperative complications, chemotherapy, radiation therapy, and lung cancer recurrence. Patients were matched 1:1 based on preoperative factors, and postoperative risk factors were evaluated using multivariate logistic regression analysis., Results: A higher proportion of men and higher prevalence of chronic lung diseases, smokers, squamous cell carcinoma (SCC), postoperative acute pneumonia, chronic pneumonia, air leak, and history of radiation therapy were noted in the PDL group than in the non-PDL group. In the analysis following propensity score matching, chronic pneumonia [odds ratio (OR): 10.1, 95% confidence interval (CI): 2.9 to 35.8] was identified as an independent risk factor for PDL., Conclusions: In this study, PDL after lung cancer surgery was associated with postoperative chronic pneumonia, including Aspergillus infection and aspiration pneumonia., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-452/coif). The authors have no conflicts of interest to declare., (2024 Journal of Thoracic Disease. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
28. Baseline genetic abnormalities and effectiveness of osimertinib treatment in patients with chemotherapy-naïve EGFR-mutated NSCLC based on performance status.
- Author
-
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa SI, Nakamura K, Mizumori Y, Shinohara T, Yanai H, Nakatomi K, Oki M, Mori M, Kuwako T, Yamazaki K, Tamura A, Ando M, and Koh Y
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Prospective Studies, Antineoplastic Agents therapeutic use, Japan, Progression-Free Survival, Aged, 80 and over, Adult, beta Catenin genetics, Indoles, Pyrimidines, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Acrylamides therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms mortality, ErbB Receptors genetics, Aniline Compounds therapeutic use, Mutation
- Abstract
Background/aim: For patients treated with osimertinib as first-line therapy, there have been no studies comparing both progression-free survival (PFS) and overall survival (OS) according to performance status (PS). Furthermore, no studies have examined differences in baseline genetic abnormalities between patients with poor and good PS. Therefore, we aimed to investigate differences in baseline genetic abnormalities and treatment effects between patients with poor and good PS who received osimertinib as the primary treatment., Patients and Methods: This is a secondary analysis of the ELUCIDATOR study, which is a multi-center prospective observational study in Japan that assessed mechanisms underlying resistance to osimertinib as first-line treatment for advanced non-small cell lung cancer with epidermal growth factor receptor mutations., Results: There were 153 and 25 patients in the good and poor PS groups, respectively. Multivariate analysis revealed no significant between-group differences in PFS (hazards ratio [HR]: 0.98, 95% confidence interval [CI]: 0.52-1.72, p = 0.946). Multivariate analysis of OS revealed that poor PS was a poor prognostic factor (HR: 2.67, 95% CI: 1.43-4.73, p = 0.003). Regarding baseline genetic abnormalities, there was a significant increase in APC-positive cases (20.0% vs. 2.2%, p = 0.009) and a trend toward more CTNNB1-positive cases in the poor PS group than in the good PS group (14.3% vs. 2.9%, p = 0.062)., Conclusion: There was no between-group difference in PFS, although OS was significantly inferior in the poor PS group. Additionally, there was a significant increase in APC-positive cases and a trend toward more CTNNB1-positive cases in the poor PS group., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: Data from the NinJa study.
- Author
-
Matsui T, Yoshida T, Nishino T, Yoshizawa S, Sawada T, and Tohma S
- Subjects
- Humans, Japan epidemiology, Male, Female, Aged, Middle Aged, Age of Onset, Methotrexate therapeutic use, Databases, Factual, Adult, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid epidemiology, Antirheumatic Agents therapeutic use
- Abstract
Objectives: Our objective was to investigate trends in the treatment of patients with late-onset rheumatoid arthritis (LORA) using data from the National Database of Rheumatic Diseases in Japan (NinJa)., Methods: Patients registered in the National Database of Rheumatic Diseases in Japan were classified according to the disease onset: at <65 years (young-onset rheumatoid arthritis); at 65-74 years (early LORA); and at ≥75 years (late LORA). Chronological changes in the treatment and disease activity were compared., Results: A total of 7178, 13,171, 15,295, and 15,943 patients were evaluated in 2010, 2013, 2016, and 2019, respectively. In all groups, the use of methotrexate gradually decreased, whereas that of biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) increased; the use of tumor necrosis factor inhibitors decreased, whereas that of non-tumor necrosis factor inhibitors increased. LORA was characterized by more single DMARD use and less methotrexate and biological/targeted synthetic DMARD use. Tumor necrosis factor inhibitors and interleukin-6 inhibitors were used less frequently, whereas abatacept was utilized more frequently in late versus early LORA. Conventional synthetic DMARD (excluding methotrexate) and glucocorticoid use was higher in late versus early LORA., Conclusions: This analysis revealed chronological changes in the treatment of LORA in Japan. Differences between early and late LORA suggest that patients are not a homogeneous population., (© Japan College of Rheumatology 2024. Published by Oxford University Press. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site–for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
30. Association of rare single nucleotide variant MUC5B rs35705950 with interstitial lung disease in Japanese rheumatoid arthritis.
- Author
-
Higuchi T, Oka S, Shimada K, Tsunoda S, Ito S, Okamoto A, Fujimori M, Nakamura T, Katayama M, Suzuki M, Saisho K, Shinohara S, Matsui T, Migita K, Nagaoka S, Tohma S, and Furukawa H
- Abstract
Objectives: Rheumatoid arthritis (RA) is sometimes complicated by interstitial lung disease (ILD) with a poor prognosis. A single nucleotide variant (SNV) in MUC5B was associated with ILD in European RA patients. However, associations of this SNV were not found in Japanese RA patients, because its frequency in Japanese populations is very low. We investigated the associations of candidate SNVs including the MUC5B variant with ILD in Japanese RA., Methods: Genotyping of MUC5B rs35705950, MUC2 rs7934606, MAD1L1 rs12699415, and PPFIBP2 rs6578890 in Japanese RA patients was conducted for association analyses., Results: MUC5B rs35705950 was associated with usual interstitial pneumonia (UIP) (p = 0.0039, Pc = 0.0156, odds ratio [OR] 10.66, 95% confidence interval [CI] 2.05-55.37) or ILD (p = 0.0071, Pc = 0.0284, OR 7.33, 95%CI 1.52-35.44) in Japanese RA under the allele model. MUC2 rs7934606 was associated with UIP (p = 0.0072, Pc = 0.0288, OR 29.55, 95%CI 1.52-574.57) or ILD (p = 0.0037, Pc = 0.0148, OR 22.95, 95%CI 1.27-416.13) in RA. Haplotype analyses suggested the primary association of MUC5B rs35705950 with UIP in Japanese RA. No significant association of MAD1L1 rs12699415 or PPFIBP2 rs6578890 with UIP, nonspecific interstitial pneumonia, or ILD in RA was observed., Conclusions: MUC5B rs35705950 is associated with, and might be involved in the pathogenesis of ILD, especially UIP, in Japanese RA., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
31. Screening rates for HIV and diabetes in patients with active TB: results of a nationwide survey in Japan.
- Author
-
Kimura Y, Sasabuchi Y, Jo T, Hashimoto Y, Kumazawa R, Ishimaru M, Matsui H, Yokoyama A, Tanaka G, and Yasunaga H
- Abstract
Competing Interests: Conflicts of interest: none declared.
- Published
- 2024
- Full Text
- View/download PDF
32. The first lichen planus case coexisting bronchiolitis obliterans without malignant tumors.
- Author
-
Nikaido T, Tanino Y, Sato Y, Togawa R, Watanabe N, Wang X, Fukuhara N, Harigane R, Saito K, Kazama K, Yamada R, Sato R, Tomita H, Rikimaru M, Suzuki Y, Minemura H, Saito J, Kanazawa K, Yamamoto T, Hashimoto Y, Hebisawa A, and Shibata Y
- Subjects
- Humans, Male, Female, Middle Aged, Lichen Planus pathology, Lichen Planus complications, Bronchiolitis Obliterans pathology, Bronchiolitis Obliterans complications, Bronchiolitis Obliterans diagnosis
- Published
- 2024
- Full Text
- View/download PDF
33. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders.
- Author
-
Hoshida Y, Tsujii A, Ohshima S, Saeki Y, Yagita M, Miyamura T, Katayama M, Kawasaki T, Hiramatsu Y, Oshima H, Murayama T, Higa S, Kuraoka K, Hirano F, Ichikawa K, Kurosawa M, Suzuki H, Chiba N, Sugiyama T, Minami Y, Niino H, Ihata A, Saito I, Mitsuo A, Maejima T, Kawashima A, Tsutani H, Takahi K, Kasai T, Shinno Y, Tachiyama Y, Teramoto N, Taguchi K, Naito S, Yoshizawa S, Ito M, Suenaga Y, Mori S, Nagakura S, Yoshikawa N, Nomoto M, Ueda A, Nagaoka S, Tsuura Y, Setoguchi K, Sugii S, Abe A, Sugaya T, Sugahara H, Fujita S, Kunugiza Y, Iizuka N, Yoshihara R, Yabe H, Fujisaki T, Morii E, Takeshita M, Sato M, Saito K, Matsui K, Tomita Y, Furukawa H, and Tohma S
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Japan, Tacrolimus therapeutic use, Tacrolimus adverse effects, Drug Therapy, Combination, Epstein-Barr Virus Infections complications, Adult, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid complications, Antirheumatic Agents therapeutic use, Antirheumatic Agents adverse effects, Lymphoproliferative Disorders chemically induced, Methotrexate therapeutic use, Tumor Necrosis Factor Inhibitors therapeutic use, Tumor Necrosis Factor Inhibitors adverse effects
- Abstract
Objective: In this study, we examine how advancements in novel antirheumatic drugs affect the clinicopathologic features of lymphoproliferative disorder (LPD) in patients with rheumatoid arthritis (RA)., Methods: In this multicenter study across 53 hospitals in Japan, we characterized patients with RA who developed LPDs and visited the hospitals between January 1999 and March 2021. The statistical tools used included Fisher's exact test, the Mann-Whitney U-test, the log-rank test, logistic regression analysis, and Cox proportional hazards models., Results: Overall, 752 patients with RA-associated LPD (RA-LPD) and 770 with sporadic LPD were included in the study. We observed significant differences in the clinicopathologic features between patients with RA-LPD and those with sporadic LPD. Histopathological analysis revealed a high frequency of LPD-associated immunosuppressive conditions. Furthermore, patients with RA-LPD were evaluated based on the antirheumatic drugs administered. The methotrexate (MTX) plus tacrolimus and MTX plus tumor necrosis factor inhibitor (TNFi) groups had different affected site frequencies and histologic subtypes than the MTX-only group. Moreover, MTX and TNFi may synergistically affect susceptibility to Epstein-Barr virus infection. In case of antirheumatic drugs administered after LPD onset, tocilizumab (TCZ)-only therapy was associated with lower frequency of regrowth after spontaneous regression than other regimens., Conclusion: Antirheumatic drugs administered before LPD onset may influence the clinicopathologic features of RA-LPD, with patterns changing over time. Furthermore, TCZ-only regimens are recommended after LPD onset., (© 2024 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
- Published
- 2024
- Full Text
- View/download PDF
34. Subjective and objective image quality of low-dose CT images processed using a self-supervised denoising algorithm.
- Author
-
Kimura Y, Suyama TQ, Shimamura Y, Suzuki J, Watanabe M, Igei H, Otera Y, Kaneko T, Suzukawa M, Matsui H, and Kudo H
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, Tomography, X-Ray Computed methods, Algorithms, Signal-To-Noise Ratio, Radiation Dosage, Image Processing, Computer-Assisted methods
- Abstract
This study aimed to assess the subjective and objective image quality of low-dose computed tomography (CT) images processed using a self-supervised denoising algorithm with deep learning. We trained the self-supervised denoising model using low-dose CT images of 40 patients and applied this model to CT images of another 30 patients. Image quality, in terms of noise and edge sharpness, was rated on a 5-point scale by two radiologists. The coefficient of variation, contrast-to-noise ratio (CNR), and signal-to-noise ratio (SNR) were calculated. The values for the self-supervised denoising model were compared with those for the original low-dose CT images and CT images processed using other conventional denoising algorithms (non-local means, block-matching and 3D filtering, and total variation minimization-based algorithms). The mean (standard deviation) scores of local and overall noise levels for the self-supervised denoising algorithm were 3.90 (0.40) and 3.93 (0.51), respectively, outperforming the original image and other algorithms. Similarly, the mean scores of local and overall edge sharpness for the self-supervised denoising algorithm were 3.90 (0.40) and 3.75 (0.47), respectively, surpassing the scores of the original image and other algorithms. The CNR and SNR for the self-supervised denoising algorithm were higher than those for the original images but slightly lower than those for the other algorithms. Our findings indicate the potential clinical applicability of the self-supervised denoising algorithm for low-dose CT images in clinical settings., (© 2024. The Author(s), under exclusive licence to Japanese Society of Radiological Technology and Japan Society of Medical Physics.)
- Published
- 2024
- Full Text
- View/download PDF
35. Stage IV gastric adenocarcinoma with enteroblastic differentiation with 5-year relapse-free survival after D2 gastrectomy and chemotherapy: A case report.
- Author
-
Nakayama H, Ida T, Hasegawa Y, Sakamoto A, Umezawa Y, Inaba Y, and Nakada H
- Abstract
Background: Gastric adenocarcinoma with enteroblastic differentiation (GACED), a rare subtype of gastric cancer, is associated with a more aggressive behavior than conventional gastric adenocarcinomas. We report a rare case of stage IV GACED treated with D2 gastrectomy and postoperative chemotherapy., Case Presentation: A 39-year-old woman with acute upper abdominal pain immediately underwent surgery for gastric perforation. Afterward she was diagnosed with adenocarcinoma of the pylorus. D2 gastrectomy was performed and the final pathological diagnosis was stage IV GACED with positive peritoneal cytology. Postoperative chemotherapy was initiated with S1 plus oxaliplatin for 1 year, which was ceased thereafter to enhance her quality of life. The patient survived more than 5 years without relapse after gastrectomy., Conclusions: Stage IV GACED, determined by positive spalt-like transcription factor 4, can be successfully treated with surgery and chemotherapy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
- Author
-
Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, and Kishi K
- Subjects
- Humans, Male, Female, Aged, Retrospective Studies, Middle Aged, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung mortality, Prognosis, Disease Progression, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Treatment Outcome, Small Cell Lung Carcinoma drug therapy, Small Cell Lung Carcinoma mortality, Aged, 80 and over, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Lung Neoplasms pathology, Idiopathic Interstitial Pneumonias drug therapy, Idiopathic Interstitial Pneumonias mortality
- Abstract
Effective treatment for advanced lung cancer and idiopathic interstitial pneumonia (IIP) remains an unmet medical need. The relationship between chemotherapy's effectiveness in advanced lung cancer and the risk of acute exacerbation of IIP is poorly investigated. There is limited evidence that patients who experience an acute exacerbation of IIPs during cytotoxic chemotherapy have poorer outcomes than those who do not. Among 1004 patients with advanced lung cancer and IIPs enrolled in our published multi-centre retrospective study from 110 Japanese institutions, 708 patients (male: female, 645:63; mean age, 70.4) received first-line chemotherapy. The occurrence of chemotherapy-triggered acute exacerbations of IIPs and overall survival (OS) were analysed. The OS between groups of patients with and without the occurrence of acute exacerbation was compared at four landmark time points (30, 60, 90, and 120 days), starting from the first-line chemotherapy, using the landmark method. The incidence of acute exacerbation in patients who received first-line chemotherapy with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) was more frequent in NSCLC patients than in SCLC (4.2% vs 12.6%; odds ratio [OR]: 3.316; 95% confidence interval [CI] 1.25-8.8). Median survival time was 9.9 months (95% CI 9.2-10.7). Patients who experienced acute exacerbation had significant worse survival outcomes than those who did not at various time points (30 days, hazard ratio [HR]: 5.191, 95% CI 2.889-9.328; 60 days, HR: 2.351, 95% CI 1.104-5.009; 90 days, HR: 2.416, 95% CI 1.232-4.739; and 120 days, HR: 2.521, 95% CI 1.357-4.681). Acute exacerbation during first-line chemotherapy can predict poor survival.Trial Registration number: UMIN000018227., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. Analysis of predictors of fever after aortic valve replacement: Diabetic patients are less likely to develop fever after aortic valve replacement, a single-centre retrospective study.
- Author
-
Ishibashi H, Enomoto Y, Takaoka S, Aoki K, Nagai H, Yamagata K, Ishibashi-Kanno N, Uchida F, Fukuzawa S, Tabuchi K, Bukawa H, Suzuki Y, and Yanagawa T
- Abstract
Background: Postoperative temperature dysregulation affects the length of hospital stay and prognosis. This study evaluated the factors that influence the occurrence of fever in patients after aortic valve replacement surgery., Methods: Eighty-seven consecutive patients who underwent aortic valve replacement surgery were included. Patients' age, sex and body mass index; presence of diabetes mellitus; operation time; blood loss; blood transfusion volume; preoperative and postoperative laboratory findings; presence or absence of oral function management; and fever >38°C were retrospectively analysed through univariate and multiple logistic regression analyses., Results: Among the variables, only diabetes mellitus status was significantly associated with fever ⩾38°C. Postoperatively, patients with diabetes mellitus were significantly less likely to develop fever above 38°C and a fever rising to 38°C., Conclusions: This study shows that the presence of comorbid diabetes mellitus decreases the frequency of developing fever >38°C after aortic valve replacement surgery., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
38. Radiological and histopathological features and treatment response by subtypes of interstitial pneumonia with autoimmune features: A prospective, multicentre cohort study.
- Author
-
Enomoto N, Yazawa S, Mochizuka Y, Fukada A, Tanaka Y, Naoi H, Aono Y, Inoue Y, Yasui H, Karayama M, Suzuki Y, Hozumi H, Furuhashi K, Toyoshima M, Kono M, Imokawa S, Sano T, Akamatsu T, Koshimizu N, Yokomura K, Matsuda H, Kaida Y, Shirai M, Mori K, Masuda M, Fujisawa T, Inui N, Nakamura Y, Sugiura H, Sumikawa H, Kitani M, Tabata K, Ogawa N, and Suda T
- Subjects
- Humans, Cohort Studies, Prospective Studies, Retrospective Studies, Autoimmune Diseases complications, Autoimmune Diseases diagnostic imaging, Lung Diseases, Interstitial diagnosis, Idiopathic Interstitial Pneumonias diagnosis, Connective Tissue Diseases complications, Connective Tissue Diseases diagnostic imaging
- Abstract
Background: Patients with idiopathic interstitial pneumonia (IIP) have a favourable prognosis when they have interstitial pneumonia with autoimmune features (IPAF). However, precise IPAF-related findings from high-resolution computed tomography (HRCT) and lung histopathological specimens and the treatment response have not been fully determined. Therefore, this study was conducted to evaluate the relationship between findings on HRCT or lung histopathological specimens and the progression of interstitial pneumonia in patients with IPAF., Methods: This multicentre cohort study prospectively enrolled consecutive patients with IIP. At the diagnosis of IIP, we systematically evaluated 74 features suggestive of connective tissue diseases and followed them up. HRCT, lung specimens, serum antibodies, and the clinical course were also evaluated., Results: Among 222 patients with IIP, 26 (11.7%) fulfilled the IPAF criteria. During a median observation period of 36 months, patients with IPAF showed better survival than those without IPAF (p = 0.034). While histopathological findings were not related to IPAF, nonspecific interstitial pneumonia (NSIP) with organizing pneumonia (OP) overlap was the most prevalent HRCT pattern (p < 0.001) and the consolidation opacity was the most common radiological finding in IPAF (p = 0.017). Furthermore, in patients with IPAF, the diagnosis of COP or NSIP with OP overlap was associated with a higher increase in %FVC in 1 year than in those with idiopathic pulmonary fibrosis, NSIP, or unclassifiable IIP (p = 0.002)., Conclusions: This study shows the presence of consolidation opacity on HRCT and the diagnosis of COP or NSIP with OP overlap are associated with IPAF and its favourable treatment response in patients with IPAF., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Noriyuki Enomoto received funding from Boehringer Ingelheim Japan Co., Ltd. All of other authors did not receive funding., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Pulmonary Hypertension With Interstitial Pneumonia: Initial Treatment Effectiveness and Severity in a Japan Registry.
- Author
-
Tanabe N, Kumamaru H, Tamura Y, Kondoh Y, Nakayama K, Kinukawa N, Kimura T, Nishiyama O, Tsujino I, Shigeta A, Morio Y, Inoue Y, Kuraishi H, Hirata KI, Tanaka K, Kuwana M, Nagaoka T, Handa T, Sugimura K, Sakamaki F, Naito A, Taniguchi Y, Matsubara H, Hanaoka M, Inami T, Hayama N, Nishimura Y, Kimura H, Miyata H, and Tatsumi K
- Abstract
Background: Recent guidelines discourage the use of pulmonary arterial hypertension (PAH)-targeted therapies in patients with pulmonary hypertension (PH) associated with respiratory diseases. Therefore, stratifications of the effectiveness of PAH-targeted therapies are important for this group., Objectives: The authors aimed to identify phenotypes that might benefit from initial PAH-targeted therapies in patients with PH associated with interstitial pneumonia and combined pulmonary fibrosis and emphysema., Methods: We categorized 270 patients with precapillary PH (192 interstitial pneumonia, 78 combined pulmonary fibrosis and emphysema) into severe and mild PH using a pulmonary vascular resistance of 5 WU. We investigated the prognostic factors and compared the prognoses of initial (within 2 months after diagnosis) and noninitial treatment groups, as well as responders (improvements in World Health Organization functional class, pulmonary vascular resistance, and 6-minute walk distance) and nonresponders., Results: Among 239 treatment-naive patients, 46.0% had severe PH, 51.8% had mild ventilatory impairment (VI), and 40.6% received initial treatment. In the severe PH with mild VI subgroup, the initial treatment group had a favorable prognosis compared with the noninitial treatment group. The response rate in this group was significantly higher than the others (48.2% vs 21.8%, ratio 2.21 [95% CI: 1.17-4.16]). In multivariate analysis, initial treatment was a better prognostic factor for severe PH but not for mild PH. Within the severe PH subgroup, responders had a favorable prognosis., Conclusions: This study demonstrated an increased number of responders to initial PAH-targeted therapy, with a favorable prognosis in severe PH cases with mild VI. A survival benefit was not observed in mild PH cases. (Multi-institutional Prospective Registry in Pulmonary Hypertension associated with Respiratory Disease; UMIN000011541)., Competing Interests: This study was supported by grants from Grant-in-Aid for Scientific Research (20FC1027, 23FC1031) from the Ministry of Health, Labour and Welfare of Japan, the Medical Research Fund of the Japan Medical Association (No. 16ek0109127h0002 and No. JP18lk1601003h0001), and the Nonprofit Organization Japan PH registry. Dr Tanabe has received remuneration from Nippon Shinyaku, Janssen Pharmaceutical K.K., and Bayer Yakuhin, and belongs to a department endowed by Nippon Shinyaku. Dr Kumamaru has received consultation fees from Mitsubishi-Tanabe Pharma Corp, and EPS Corp; speaker fee from Chugai Pharmaceutical Co, Ltd; and a research grant from Pfizer Japan Inc. Drs Kumamaru, Kinukawa, and Miyata are affiliated with the Department of Health Quality Assessment at the University of Tokyo, a social collaboration department supported by the National Clinical Database, Johnson & Johnson K.K., Nipro Corp, and Intuitive Surgical Sàrl. Dr Nishiyama has received remuneration from Nippon Shinyaku, Janssen Pharmaceutical K.K., and Boehringer Ingelheim. Dr Tsujino has received remuneration from Nippon Shinyaku and Janssen Pharmaceutical K.K., and belongs to a department endowed by Nippon Shinyaku, Mochida Pharmaceutical Co Ltd, Boehringer Ingelheim, Takeyama Co, Ltd, Kaneka Medics Co, and Medical System Network Co Ltd. Dr Inoue has received remuneration from Boehringer Ingelheim. Dr Hirata has received a research grant from Janssen Pharmaceutical K.K. Dr Kuwana has received remuneration from Nippon Shinyaku. Dr Handa has received a research grant from Fujifilm Corp and belongs to a department endowed by Teijin Pharma Ltd. Dr Taniguchi has received a research grant from Janssen Pharmaceutical K.K. Dr Matsubara has received remuneration from Nippon Shinyaku, Janssen Pharmaceutical K.K., Bayer Yakuhin, Mochida Pharmaceutical. Co Ltd, and Kaneka Medics Co; and research grants from Nippon Shinyaku, Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co Ltd, and Insmed Incorporated. Dr Tatsumi has received remuneration from Janssen Pharmaceutical K.K. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
40. PLA2R-positive membranous nephropathy in IgG4-related disease.
- Author
-
Ushio Y, Akihisa T, Karasawa K, Seki M, Kobayashi S, Miyabe Y, Kataoka H, Ito N, Taneda S, Akiyama S, Hebisawa A, Kawano M, Honda K, and Hoshino J
- Subjects
- Male, Humans, Aged, Receptors, Phospholipase A2, Immunoglobulin G, Autoantibodies, Glomerulonephritis, Membranous complications, Glomerulonephritis, Membranous diagnosis, Immunoglobulin G4-Related Disease complications, Immunoglobulin G4-Related Disease diagnosis, Nephrotic Syndrome complications, Nephritis, Interstitial complications, Nephritis, Interstitial diagnosis
- Abstract
Background: IgG4-related disease (IgG4-RD) is a fibroinflammatory disease that affects multiple organs, including the pancreas, lacrimal glands, salivary glands, periaortic/retroperitoneum, and kidney. Interstitial nephritis is a typical renal disorder associated with IgG4-RD, but membranous nephropathy is also seen in some cases., Case Presentation: Herein we report on the case of a 77-year-old male patient with nephrotic syndrome and IgG4-related lung disease. His serum phospholipase A2 receptor (PLA2R) antibody was positive. His renal biopsy specimen was also positive for PLA2R. The renal biopsy specimen showed membranous nephropathy with equal IgG3 and IgG4 immunofluorescence staining and no interstitial nephritis, suggesting IgG4-RD manifesting as membranous nephropathy., Conclusions: Nephrotic syndrome caused by membranous nephropathy is sometimes associated with IgG4-RD. In such cases, even if serum PLA2R antibody is positive, it should be considered that the membranous nephropathy may be secondary to IgG4-RD., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
41. Bayesian parametric estimation based on left-truncated competing risks data under bivariate Clayton copula models.
- Author
-
Michimae H, Emura T, Miyamoto A, and Kishi K
- Abstract
In observational/field studies, competing risks and left-truncation may co-exist, yielding 'left-truncated competing risks' settings. Under the assumption of independent competing risks, parametric estimation methods were developed for left-truncated competing risks data. However, competing risks may be dependent in real applications. In this paper, we propose a Bayesian estimator for both independent competing risks and copula-based dependent competing risks models under left-truncation. The simulations show that the Bayesian estimator for the copula-based dependent risks model yields the desired performance when competing risks are dependent. We also comprehensively explore the choice of the prior distributions (Gamma, Inverse-Gamma, Uniform, half Normal and half Cauchy) and hyperparameters via simulations. Finally, two real datasets are analyzed to demonstrate the proposed estimators., Competing Interests: No potential conflict of interest was reported by the author(s)., (© 2024 Informa UK Limited, trading as Taylor & Francis Group.)
- Published
- 2024
- Full Text
- View/download PDF
42. High attenuation mucus in bronchi with allergic bronchopulmonary mycosis.
- Author
-
Hattori S, Oguma T, Ishiguro T, Suzuki J, Fukunaga K, Shimoda T, Kimura H, Obase Y, Okada N, Tanaka J, Kitahara A, Tomomatsu K, Shiraishi Y, and Asano K
- Subjects
- Humans, Retrospective Studies, Bronchi, Mucus, Invasive Pulmonary Aspergillosis, Aspergillosis, Allergic Bronchopulmonary diagnostic imaging
- Abstract
Background: High-attenuation mucus (HAM) is a specific manifestation of allergic bronchopulmonary mycosis (ABPM) on chest computed tomography (CT)., Objectives: To compare the diagnostic accuracy of the two definitions of HAM and to clarify the clinical and radiographic characteristics of HAM-positive and HAM-negative ABPM., Methods: CT images at the diagnosis of ABPM using Asano's criteria were retrospectively analysed. In Study #1, radiographic data obtained using the same CT apparatus in a single institute were analysed to determine the agreement between the two definitions of HAM: a mucus plug that is visually denser than the paraspinal muscles or that with a radiodensity ≥70 Hounsfield units. In Study #2, HAM was diagnosed by comparison with the paraspinal muscles in patients with ABPM reporting to 14 medical institutes in Japan., Results: In Study #1, 93 mucus plugs from 26 patients were analysed. A substantial agreement for HAM diagnosis was observed between the two methods, with a κ coefficient of 0.72. In Study #2, 60 cases of ABPM were analysed; mucus plugs were present in all cases and HAM was diagnosed in 45 (75%) cases. The median A. fumigatus-specific IgE titre was significantly lower in HAM-positive patients than in HAM-negative patients (2.5 vs. 24.3 U
A /mL, p = .004). Nodular shadows were observed more frequently in the airways distal to HAM than in those distal to non-HAM mucus plugs (59% vs. 32%, p < .001)., Conclusion: In conclusion, agreement between the two methods to diagnose HAM was substantial. HAM was associated with some immunological and radiographic characteristics, including lower levels of sensitization to A. fumigatus and the presence of distal airway lesions., (© 2024 Wiley-VCH GmbH. Published by John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
43. Human leucocyte antigens and Japanese patients with polymyalgia rheumatica: the protective effect of DRB1*09:01 .
- Author
-
Nogi S, Oka S, Higuchi T, Furukawa H, Shimada K, Azuma T, Sugiyama T, Hirano F, Okamoto A, Fujimori M, Horai Y, Ihata A, Hashimoto A, Komiya A, Matsui T, Fukui N, Katayama M, Migita K, and Tohma S
- Subjects
- Humans, Epitopes, HLA Antigens, Japan epidemiology, Pain, Giant Cell Arteritis genetics, Polymyalgia Rheumatica epidemiology, Polymyalgia Rheumatica genetics, HLA-DR Antigens genetics
- Abstract
Objective: The hallmarks of the chronic inflammatory disease polymyalgia rheumatica (PMR) include pain, and morning stiffness in areas of the neck, shoulder and pelvic girdle. The human leucocyte antigen ( HLA ) gene was reported to be an important risk factor for PMR, but it has not been analysed precisely, especially in populations other than Europeans., Methods: Genotyping of DRB1 and DQB1 was performed in Japanese PMR patients (n=270) and controls (n=413). Associations between allele carrier and genotype frequencies were determined for PMR., Results: DRB1*04:05 was associated with a predisposition to PMR (p=0.0006, Pc =0.0193, OR 1.85, 95% CI 1.31 to 2.62). DRB1*09:01 was associated with protection against PMR (p=1.46×10
-5 , Pc =0.0004, OR 0.40, 95% CI 0.26 to 0.61). A shared epitope (SE) associated with PMR (p=3.07×10-6 , OR 2.11, 95% CI 1.54 to 2.88). DQB1*03:03 (p=0.0010, P c=0.0140, OR 0.52, 95% CI 0.35 to 0.77) was associated with protection against PMR and DQB1*04:01 (p=0.0009, P c=0.0140, OR 1.82, 95% CI 1.28 to 2.58) was associated with predisposition to PMR. A gene dosage effect was observed for DRB1*09:01 and DQB1*03:03 , but not for DRB1*04:05, SE or DQB1*04:01 . Haplotype and logistic regression analyses suggested a protective effect for DRB1*09:01 ., Conclusion: This study is the first to demonstrate predisposing associations of DRB1*04:05, SE, and DQB1*04:01 , and protective associations of DRB1*09:01 and DQB1*03:03 with PMR in Japanese patients. Our data indicate HLA has predisposing and protective effects on the pathogenesis of PMR., Competing Interests: Competing interests: ST was supported by research grants from Astellas Pharma,Teijin Pharma, Mitsubishi Tanabe Pharma, Abbott Japan, Merck Sharp and Dohme, Takeda Pharmaceutical Company, Eisai, Chugai Pharmaceutical and Pfizer Japan. ST received honoraria from Chugai Pharmaceutical, Pfizer Japan, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical, Asahi Kasei Pharma Corporation, Astellas Pharma and AbbVie GK. HF received honoraria from Pfizer Japan, Takeda Pharmaceutical Company, Dainippon Sumitomo Pharma, Luminex Japan Corporatio, Ayumi Pharmaceutical Corporation, Daiichi Sankyo and Ajinomoto. HF was supported by grants from Daiwa Securities Health Foundation, Takeda Science Foundation, Takeda Science Foundation, Bristol-Myers-Squibb Co., the Nakatomi Foundation, Japan Research Foundation for Clinical Pharmacology and Mitsui Sumitomo Insurance Welfare Foundation., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2024
- Full Text
- View/download PDF
44. Chronic Pulmonary Aspergillosis Caused by Aspergillus tubingensis Diagnosed by a Bronchoscopic Biopsy.
- Author
-
Sekiguchi R, Takeda K, Suzuki J, Enomoto Y, Kitani M, Narumoto O, Tashimo H, Yamane A, Nagai H, Watanabe A, Kamei K, and Matsui H
- Subjects
- Male, Humans, Aged, Lung diagnostic imaging, Aspergillus, Pulmonary Aspergillosis complications, Pulmonary Aspergillosis diagnosis
- Abstract
We herein report a case of chronic pulmonary aspergillosis (CPA) caused by Aspergillus tubingensis diagnosed by a bronchoscopic biopsy with negative serological and sputum culture findings. A 66-year-old man was referred for the assessment of a pulmonary cavity. Computed tomography showed a thick-walled cavity in the upper right pulmonary lobe. Serum β-D glucan, Aspergillus galactomannan, and Aspergillus antibody tests were negative. Aspergillus species were not detected in the sputum. Culture and pathological specimens were obtained from the mass by bronchoscopy. Microscopic examination findings were consistent with Aspergillus niger complex morphologically and identified as Aspergillus tubingensis through DNA sequencing. The patient was diagnosed with chronic pulmonary aspergillosis.
- Published
- 2024
- Full Text
- View/download PDF
45. Low Serum IL-18 Levels May Predict the Effectiveness of Dupilumab in Severe Asthma.
- Author
-
Watanabe S, Suzukawa M, Tashimo H, Ohshima N, Asari I, Takada K, Imoto S, Nagase T, and Ohta K
- Subjects
- Humans, Interleukin-18 therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Eosinophils, Cytokines, Asthma drug therapy, Anti-Asthmatic Agents therapeutic use
- Abstract
Objective Dupilumab, a monoclonal antibody specific for the human interleukin (IL)-4 receptor α, is used to treat severe asthma, especially in patients with elevated blood eosinophil counts and fractional exhaled nitric oxide (FeNO). The therapeutic response to dupilumab is highly variable. In this study, we explored new serum biomarkers to accurately predict the effect of dupilumab and examine the effect of dupilumab based on changes in the clinical parameters and cytokine levels. Methods Seventeen patients with severe asthma treated with dupilumab were enrolled. Responders, defined as those with a >0.5-point decrease in the Asthma Control Questionnaire (ACQ) score after 6 months of treatment, were included. Results There were 10 responders and 7 non-responders. Serum type 2 cytokines were equivalent between responders and non-responders; the baseline serum IL-18 level was significantly lower in responders than in non-responders (responders, 194.9±51.0 pg/mL; non-responders, 323.4±122.7 pg/mL, p=0.013). The cut-off value of IL-18 at 230.5 pg/mL could be used to distinguish non-responders from responders (sensitivity 71.4, specificity 80.0, p=0.032). Conclusion A low baseline serum IL-18 level may be a useful predictor of an unfavorable response to dupilumab in terms of the ACQ-6.
- Published
- 2024
- Full Text
- View/download PDF
46. The contributions of deleterious rare alleles in NLRP12 and inflammasome-related genes to polymyalgia rheumatica.
- Author
-
Higuchi T, Oka S, Furukawa H, and Tohma S
- Subjects
- Humans, Inflammasomes genetics, Alleles, Gene Frequency, Intracellular Signaling Peptides and Proteins genetics, Polymyalgia Rheumatica genetics, Polymyalgia Rheumatica pathology, Giant Cell Arteritis pathology
- Abstract
Polymyalgia rheumatica (PMR) is a chronic inflammatory disease characterized by arthralgia and myalgia of the shoulder and hip girdles, and fever. PMR is linked to autoimmune diseases and autoinflammatory disorders. Exome sequencing has revealed the roles of rare variants in some diseases. Causative genes for monogenic autoinflammatory disorders might be candidate genes for the selective exome analysis of PMR. We investigated rare variants in the coding and boundary regions of candidate genes for PMR. Exome sequencing was performed to analyze deleterious rare variants in candidate genes, and the frequencies of the deleterious rare alleles in PMR were compared with those of Japanese population controls. Deleterious rare alleles in the NLRL12 gene were associated with PMR (P = 0.0069, Pc = 0.0415, odds ratio [OR] 4.49, 95% confidence interval [CI] 1.79-11.27). A multigene analysis demonstrated the deleterious rare allele frequency of the candidate genes for autoinflammatory disorders was also increased in PMR (P = 0.0016, OR 3.69, 95%CI 1.81-7.54). The deleterious rare allele frequencies of the candidate genes including NLRP12 were increased in PMR patients, showing links to autoinflammatory disorders in the pathogenesis of PMR., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
47. Clinical characteristics of allergic bronchopulmonary mycosis caused by Schizophyllum commune.
- Author
-
Oguma T, Ishiguro T, Kamei K, Tanaka J, Suzuki J, Hebisawa A, Obase Y, Mukae H, Tanosaki T, Furusho S, Kurokawa K, Watai K, Matsuse H, Harada N, Nakamura A, Shibayama T, Baba R, Fukunaga K, Matsumoto H, Ohba H, Sakamoto S, Suzuki S, Tanaka S, Yamada T, Yamasaki A, Fukutomi Y, Shiraishi Y, Toyotome T, Fukunaga K, Shimoda T, Konno S, Taniguchi M, Tomomatsu K, Okada N, and Asano K
- Abstract
Background: Allergic bronchopulmonary mycosis (ABPM) is an allergic disease caused by type I and type III hypersensitivity to environmental fungi. Schizophyllum commune, a basidiomycete fungus, is one of the most common fungi that causes non-Aspergillus ABPM., Objective: Herein, we attempted to clarify the clinical characteristics of ABPM caused by S. commune (ABPM-Sc) compared with those of allergic bronchopulmonary aspergillosis (ABPA)., Methods: Patients with ABPM-Sc or ABPA were recruited from a nationwide survey in Japan, a multicenter cohort, and a fungal database at the Medical Mycology Research Center of Chiba University. The definition of culture-positive ABPM-Sc/ABPA is as follows: (1) fulfills five or more of the 10 diagnostic criteria for ABPM proposed by Asano et al., and (2) positive culture of S. commune/Aspergillus spp. in sputum, bronchial lavage fluid, or mucus plugs in the bronchi., Results: Thirty patients with ABPM-Sc and 46 with ABPA were recruited. Patients with ABPM-Sc exhibited less severe asthma and presented with better pulmonary function than those with ABPA (p = 0.008-0.03). Central bronchiectasis was more common in ABPM-Sc than that in ABPA, whereas peripheral lung lesions, including infiltrates/ground-glass opacities or fibrotic/cystic changes, were less frequent in ABPM-Sc. Aspergillus fumigatus-specific immunoglobulin (Ig)E was negative in 10 patients (34%) with ABPM-Sc, who demonstrated a lower prevalence of asthma and levels of total serum IgE than those with ABPM-Sc positive for A. fumigatus-specific IgE or ABPA., Conclusions: Clinical characteristics of ABPM-Sc, especially those negative for A. fumigatus-specific IgE, differed from those of ABPA., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)
- Published
- 2024
- Full Text
- View/download PDF
48. Factors associated with impaired physical function in elderly rheumatoid arthritis patients who had achieved low disease activity.
- Author
-
Komiya Y, Sugihara T, Hirano F, Matsumoto T, Kamiya M, Sasaki H, Hosoya T, Kimura N, Ishizaki T, Mori M, Tohma S, Yasuda S, and Matsui T
- Subjects
- Middle Aged, Aged, Humans, Methotrexate therapeutic use, Treatment Outcome, Glucocorticoids therapeutic use, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid drug therapy, Antirheumatic Agents therapeutic use
- Abstract
Objectives: We aimed to investigate factors associated with impaired physical function [defined as Health Assessment Questionnaire Disability Index (HAQ-DI) >0.5] of old-old (aged 75-84 years) patients with rheumatoid arthritis., Methods: Data from 15,185 rheumatoid arthritis patients in the National Database of Rheumatic Disease in Japan were extracted from 2017 to 2018. We enrolled 3708 patients aged 55-84 years in Simplified Disease Activity Index (SDAI) ≤11 and Steinbrocker Stage I/II. Factors associated with HAQ-DI >0.5 were analysed by multivariable logistic regression., Results: About half of the old-old patients received methotrexate, which was lower than middle-aged (55-64 years) and young-old patients (65-74 years). The proportion of glucocorticoids in the old-old patients was highest among the three groups, and biological disease-modifying antirheumatic drugs were similarly used. The prevalence of HAQ-DI >0.5 was significantly higher in old-old patients with low disease activity than in those with remission. The same was true in the middle-aged and young-old patients. Multivariable analysis showed age, higher SDAI, glucocorticoid use, and methotrexate nonuse were significantly associated with HAQ-DI >0.5 in the old-old patients., Conclusions: Achieving SDAI remission was an ideal goal for old-old patients in terms of physical function. Glucocorticoids and a low proportion of methotrexate use may influence the physical function of old-old patients., (© Japan College of Rheumatology 2023. Published by Oxford University Press.)
- Published
- 2023
- Full Text
- View/download PDF
49. Cancer-Chemotherapy-Related Regimen Checks Performed by Pharmacists of General Hospitals Other than Cancer Treatment Collaborative Base Hospitals: A Multicenter, Prospective Survey.
- Author
-
Ueki D, Suzuki S, Ohta T, Shinohara A, Ohashi Y, Konuma D, Ryushima Y, Udagawa R, Motoshige H, Ieoka M, Taji A, Kogure Y, Hiraike M, Uoi M, Ino K, Kawasaki T, and Yamaguchi M
- Abstract
Although prescription review is an important role for pharmacists in anticancer drug therapy, there are no guidelines in Japan that specify what pharmacists should check for in chemotherapy regimens. This prospective multicenter survey aimed to investigate the implementation of chemotherapy regimen checks by pharmacists in general hospitals by focusing on 19 recommended confirmation items designed to enhance chemotherapy safety. This study involved 14 hospitals within the National Hospital Organization in different regions of Japan. The top five cancers in Japan (gastric, colorectal, lung, breast, and gynecological) were targeted and specific chemotherapy regimens were analyzed. This study assessed the amount of time required for regimen checks, the number of confirmation items completed, the number and the content of inquiries raised regarding prescriptions, and the pharmacists' opinions using a questionnaire that had a maximum score of 10 points. Pharmacists checked 345 and 375 chemotherapies of patients in the control group (CG) and recommended items group (RIG), respectively. The mean time periods required for completing a chemotherapy regimen check were 4 min and 14 s (SD ±1 min and 50 s) and 6 min and 18 s (SD, ±1 min and 7 s) in the CG and RIG, respectively. The mean of the recommended items for the CG = 12.4 and for the RIG = 18.6. The items that the pharmacists did not confirm included urine protein (sixty-nine cases, 18.4%), allergy history (four cases, 1%), previous history (two cases, 0.5%), and a previous history of hepatitis B virus (sixty-nine cases, 18.4%). The number of inquiries for a doctor's prescription order was higher in the RIG than in the CG (41 vs. 27 cases). This multicenter survey demonstrated the potential effectiveness of implementing 19 recommended confirmation items in the regimen checks by pharmacists in general hospitals other than cancer treatment collaborative base hospitals.
- Published
- 2023
- Full Text
- View/download PDF
50. Association of a Single Nucleotide Variant in TERT with Airway Disease in Japanese Rheumatoid Arthritis Patients.
- Author
-
Higuchi T, Oka S, Furukawa H, Shimada K, Tsunoda S, Ito S, Okamoto A, Fujimori M, Nakamura T, Katayama M, Saisho K, Shinohara S, Matsui T, Migita K, Nagaoka S, and Tohma S
- Subjects
- Humans, Aged, East Asian People, Nucleotides, Lung Diseases, Interstitial genetics, Lung Diseases, Interstitial complications, Idiopathic Pulmonary Fibrosis genetics, Arthritis, Rheumatoid genetics, Telomerase genetics
- Abstract
Interstitial lung disease and airway disease (AD) are often complicated with rheumatoid arthritis (RA) and have a poor prognosis. Several studies reported genetic associations with interstitial lung disease in RA. However, few genetic studies have examined the susceptibility to AD in RA patients. Here, we investigated whether single nucleotide variants susceptible to idiopathic pulmonary fibrosis might be associated with interstitial lung disease or AD in Japanese RA patients. Genotyping of rs2736100 [C/A] in TERT and rs1278769 [G/A] in ATP11A was conducted in 98 RA patients with usual interstitial pneumonia, 120 with nonspecific interstitial pneumonia (NSIP), 227 with AD, and 422 without chronic lung disease using TaqMan assays. An association with AD in RA was found for rs2736100 ( p = 0.0043, Pc = 0.0129, odds ratio [OR] 1.40, 95% confidence interval [CI] 1.11-1.77). ATP11A rs1278769 was significantly associated with NSIP in older RA patients (>65 years, p = 0.0010, OR 2.15, 95% CI 1.35-3.40). This study first reported an association of rs2736100 with AD in RA patients and ATP11A rs1278769 with NSIP in older RA patients.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.